Research, development and evaluation strategies for pharmaceutical education and the workforce: A global report by Bader, L & Bates, I
2017
Research, development 
and evaluation strategies 
for pharmaceutical 
education and 
the workforce: 
Copyright © 2017 International Pharmaceutical Federation (FIP)
A global report
1 | Research, Development and Evaluation Strategies
................
Colophon
Copyright© 2017 International Pharmaceutical Federation 
(FIP)
Fédération Internationale Pharmaceutique (FIP)
Andries Bickerweg 5
2517 JP The Hague
The Netherlands
www.fip.org - fip@fip.org
All rights reserved. No part of this publication may be stored in any retrieval system or transcribed by any form or means — 
eletronic, mechanical, recording, or otherwise — without citation of the source. FIP shall not be held liable for any damages 
incurred resulting from the use of any data and information from this report. All measures have been taken to ensure accuracy of 
the data and information presented in this report.
This report is available for electronic download from: www.fip.org/educationreports
Editors: 
  
                Lina R. Bader, FIP Education (FIPEd) Project Coordinator and Researcher 
                                         Ian Bates, Director of the FIPEd Development Team, FIP-UCL Collaborating Centre, 
                University College London, School of Pharmacy
ISBN 978-0-902936-41-6
Design: 
Tiago Tomé
 
Recommended citation: 
International Pharmaceutical Federation (FIP). Research, development and evaluation strategies for pharmaceutical education 
and the workforce: A global report. The Hague: International Pharmaceutical Federation; 2017.
...............
2Research, Development and Evaluation Strategies | 
Contents
Foreword    
              
Executive summary  
Part 1 Introduction and background            
Part 2 Progress towards the Pharmaceutical Workforce Development Goals (PWDGs)      
Part 3 Strategies for advancing the global pharmaceutical workforce agenda       
               3.1    Evaluation and impact for global workforce development
               3.2    From workforce intelligence to workforce development
               3.3    Building academic capacity and the academic workforce
               3.4    Leadership development: preparing the pharmaceutical workforce
                  
Part 4 Research and development in technology-driven education            
                                 
Part 5 Summary and conclusions          
  
Annexes
Annex 1   Pharmaceutical Workforce Development Goals (PWDGs)       
Annex 2   PWDGs alignment with global health workforce strategies
Annex 3   Overview of FIPEd tools
Annex 4   Acknowledgements     
3
4
6
9
 
31
31
37
40
45
52
57
59
59
64
66
70
3 | Research, Development and Evaluation Strategies
Foreword
The International Pharmaceutical Federation (FIP) hosted the first Global Conference on Pharmacy and Pharmaceutical Sciences 
Education in Nanjing, China, on 7 & 8 November 2016. The global conference was an exceptional event that gathered pharmacy 
leaders from around the world to create a globally shared vision for transformative pharmacy and pharmaceutical sciences 
education.
Following an extensive consensus-based consultation process, three critical documents that set the future milestones for 
workforce development through education were adopted at the global conference: (1) a Global Vision for Education and 
Workforce, (2) Pharmaceutical Workforce Development Goals, and (3) Statements on Pharmacy and Pharmaceutical Sciences 
Education ("the Nanjing Statements"). 
The global vision describes the future directions of our profession and how education can support the evolution of science 
and practice. A set of 13 Pharmaceutical Workforce Development Goals aim to facilitate the implementation of the global vision 
through a series of measurable, feasible and tangible goals. The Nanjing Statements are a set of 67 statements that describe 
an envisioned future for education, to enable the enhancement of professional education standards worldwide. 
A full report of the global conference, “Transforming Pharmacy and Pharmaceutical Sciences Education in the Context 
of Workforce Development”, was launched in May 2017. Through the report, FIP calls on leaders in pharmacy practice, 
pharmaceutical education and other key stakeholders to support and advocate the implementation of these key outcomes in 
their countries. 
Under the aegis of FIP Education (FIPEd), FIP is committed to inform, guide and support the strategic planning and 
implementation of the outcomes to facilitate the transformation of the global pharmaceutical workforce in line with overall 
health workforce strategies promoted by national and international agencies. 
Research, development and evaluation are key mechanisms for strategy implementation and this report widens the evidence 
base for research, development and evaluation strategies for pharmaceutical education and the workforce. With evidence-based 
expert recommendations and comprehensive case studies from 21 countries around the world, the report provides guidance 
on aligning national research, development and evaluation projects with the global vision and Pharmaceutical Workforce 
Development Goals. 
This document is intended for all members of the pharmaceutical workforce, pharmacy leaders, governments and other 
stakeholders to catalyse needs-based planning, priority setting and forward action towards implementing the global vision. 
The report is also intended as a tool for member organisations to help prioritise and facilitate the adoption of the 
Pharmaceutical Workforce Development Goals in the context of their national strategies on health and workforce development.
FIPEd — armed with a clear, shared global vision — is committed now more than ever to advance the global pharmaceutical 
workforce in the context of education and training. The first FIPEd publication following the launch of the Nanjing roadmap, this 
report aims to enable global action to transform the pharmaceutical workforce in line with the newly adopted global roadmap.
               
                 William N. Charman, BPharm, PhD 
                 FIP Education (FIPEd) Executive Committee Chair
                 Sir John Monash Distinguished Professor 
                 Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
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1.6 The pharmaceutical workforce needs to be continually 
monitored and assessed in order to evaluate various 
capacity challenges; however further work is also 
needed to develop professional, economic and 
disease indicators to better describe the impact of 
the pharmaceutical workforce. Academic capacity in 
particular, and the training of the next generation of 
scientists and teachers, is an essential component of 
these workforce intelligence objectives.
1.7 The literature on leadership development in pharmacy 
is under-researched and little is known about the 
global status of pharmacy leadership strategies; 
paradoxically, leadership development remains a 
challenge, and concerted action is required to drive 
evidence-generation in this area. Country-level 
leadership bodies should ensure the creation of clear 
and accessible leadership development programmes 
and opportunities for their pharmaceutical workforce; 
this report provides good examples where this has 
been the case. Additionally, implementation of 
leadership development strategies should integrate 
with other aspects of workforce development such as 
academic capacity, workforce diversity and equality, 
and quality assurance.
1.8 Educational research and evaluation agenda in 
pharmacy needs strengthening and it is clear that 
better ways of evaluating the impact of technology-
driven education need to be developed and used more 
routinely by education providers.
1.9 This report provides a starting point for describing our 
current global baseline in a broad context of workforce 
and educational development. Similarly, within the 
context of a valid global vision for transforming 
the workforce we should be identifying our current 
position, across all of the PWDGs, in order to plan for 
structured collective development.
1.10 It is also clear that for some PWDGs, there is a wider 
gap in relation to others; workforce gender and 
diversity policy formation have less traction than, for 
example, competency development or continuing 
professional development strategy development.
1. Key messages
1.1 Healthcare access and delivery faces significant 
global and local challenges; rising demand, increasing 
co-morbidities and demand for medicines expertise 
particularly stand out for our profession. Investing in 
the scale up of the health workforce around the world 
to meet this general demand is a clear objective shared 
collectively by the World Health Organization, United 
Nations agencies, and other global leadership bodies.
1.2 Research, development and evaluation mechanisms 
are integral to achieving progress on our Global Vision 
for Education and Workforceª and the Pharmaceutical 
Workforce Development Goalsb (PWDGs). Global 
engagement to make research, development and 
evaluation strategies an important consideration 
for implementing the pharmaceutical workforce 
development agenda is a critical next step for our 
profession.
1.3 The first FIPEd publication following the launch of the 
Nanjing roadmap, this report starts the discussion 
to share and evaluate the state of global research, 
development and evaluation mechanisms that will 
support national leadership bodies and member 
organisations in the effective implementation of a 
needs-based pharmaceutical workforce development 
roadmap guided by the Nanjing outcomes.
1.4 Data was collected from 21 countries around the 
world to better understand their national-level 
research, development and evaluation strategies 
for the pharmaceutical workforce and how they are 
aligned with the PWDGs. The PWDGs are aimed to be 
a set of measurable, feasible and achievable goals. 
The ability to align national strategies with the goals 
show that they can be measurable. Collectively, the 
high alignment between current strategies, projects 
and initiatives demonstrate that the goals are also 
achievable. While progress towards achieving the 
PWDGs varies greatly across countries, all countries 
– regardless of economic status – have reported 
some degree of alignment with this global structure 
indicating strongly that implementation of the PWDGs 
is feasible and adaptable to local needs. 
1.5 An understanding of how to evaluate the impact of the 
pharmaceutical workforce is necessary, yet generally 
missing from the research literature. A hybrid model 
is presented as a first step in stimulating a research 
discussion on impact measurement and experts and 
researchers should begin to develop critical thinking 
in this area, particularly a more focused report on 
evaluation methodology. 
EXECUTIVE SUMMARY
a  -   Global Vision for Education and the Workforce. Presented at the Global 
Conference on Pharmacy and Pharmaceutical Sciences Education. Available 
from: http://fip.org/educationreports
b  -   Pharmaceutical Workforce Development Goals. Presented at the Global 
Conference on Pharmacy and Pharmaceutical Sciences Education. Available 
from: http://fip.org/educationreports
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1.11 It has also become clear (and noted in previous FIPEd 
reports) that terminology describing workforce and 
education is in danger of becoming confusing. A 
database of terminology would be able to identify 
and describe points of equivalence within the global 
workforce lexicon.
1.12 In conclusion, the country case studies show that there 
is high alignment between current global strategies 
and the PWDGs which creates a tangible context 
of relevance and usefulness for global workforce 
transformation; this initial evidence supports the 
notion that the FIPEd vision and PWDGs are what 
they are intended to be: measurable, feasible 
and achievable. Leadership bodies and member 
organisations should consider the incorporation of this 
global structure for meaningful national workforce 
development and progression.
6Research, Development and Evaluation Strategies | 
The outcome of this tripartite collaboration is Working 
for Health: A Five-Year Action Plan for Health Employment 
and Inclusive Economic Growth (2017–21).5 The Five-Year 
Action Plan, discussed and adopted at the 70th World Health 
Assembly, demonstrates how ILO, OECD and WHO will respond 
to each recommendation with a set of Deliverables that will 
support Member States in translating these recommendations 
into actions.
Research, development and evaluation mechanisms 
are central to the effective implementation of the UN 
Recommendations as well as the WHO Global Strategy on HRH. 
The 10th UN Recommendation calls on national, regional and 
global initiatives to:
“Undertake robust research and analysis of health labour 
markets, using harmonized metrics and methodologies, to 
strengthen evidence, accountability and action.” 
To implement this recommendation, the WHO-ILO-OECD 
describe the need for a establishing a strategic research plan 
and expanding an evidence base to inform health workforce 
investment strategies through the following Deliverable: 
“A health workforce research agenda established, research 
methodologies advanced, and evidence base expanded 
for decent work and effective health labour market 
interventions that optimize the socioeconomic returns on 
health workforce investments.”
Transforming and scaling up all health workforces and their 
education and training relies on well-coordinated, needs-
based research, development and evaluation strategies 
designed for implementation on a national-level.
1.2 Why is this important for pharmacy?
As medicines experts, the pharmaceutical workforcec plays a 
key role in improving health outcomes through responsible 
use of medicines and optimising effective choice and use. 
Investing in the development of an adaptable, flexible, 
competent and well-distributed pharmaceutical workforce 
contributes towards achieving UHC, SDGs and strengthening 
health systems. Transforming the global pharmaceutical 
workforce requires a global vision with clear and consensus-
based objectives consistent with global health strategies. 
The International Pharmaceutical Federation (FIP), as the 
global professional leadership body representing over 4 
million pharmacists and pharmaceutical scientists around 
the world, has developed a transformative workforce 
roadmap adopted at the Global Conference on Pharmacy and 
Pharmaceutical Sciences Education held in Nanjing, China, on 
7 and 8 November 2016. The workforce roadmap sets out the 
desired milestones for education and workforce development 
of the pharmaceutical workforce, clearly linked with a global 
vision for transforming pharmacy and pharmaceutical 
sciences education. 
Authors: 
Lina R. Bader, FIP Education (FIPEd) Project Coordinator and 
Researcher (lina@fip.org); Ema Paulino, Professional Secretary 
of FIP, President of the South and Autonomous Regions 
Branch and member of the National Board of the Portuguese 
Pharmaceutical Society (professionalsecretary@fip.org); 
Ian Bates, Director of the FIPEd Development Team, FIP-UCL 
Collaborating Centre, University College London, School of 
Pharmacy (i.bates@ucl.ac.uk).
1.1 Why focus on research, development 
and evaluation?
The UN Sustainable Development Goal (SDG) 3 makes a 
universal commitment to: “Ensure healthy lives and promote 
well-being for all at all ages”.1 To meet this health goal, 
progress must be made towards achieving its underlying 
targets in the years leading up to 2030. One particularly critical 
health target addresses the global health workforce and calls 
to:
“Substantially increase health financing and the 
recruitment, development, training and retention of the 
health workforce in developing countries, especially in 
least developed countries and small island developing 
States.”
The importance of this target is reflected in the major 
initiatives led by global agencies to advance the health 
workforce development agenda. The World Health 
Organization (WHO) Global Strategy on Human Resources for 
Health: Workforce 2030 was developed to advance progress 
towards the UN SDGs and universal health coverage (UHC) 
by ensuring equitable access to health workers within 
strengthened health systems.2
Significant challenges stand in the face of ensuring equitable 
access to health workers by all. The continuously rising 
demand for scaling up the health workforce around the 
world, coupled with the projected shortages of 18 million 
health workers in low- and middle- income countries,3 led to 
the establishment of the High-Level Commission on Health 
Employment and Economic Growth (the Commission) by the 
United Nations (UN). 
The UN Commission, charged with proposing actions to 
stimulate investments in human resources for health 
(HRH), made ten recommendations to transform the health 
workforce to achieve the 2030 Sustainable Development 
agenda.4 The recommendations present ambitious change-
enabling solutions that focus on transformative investments 
in the health workforce. The WHO partnered with the 
International Labour Organisation (ILO) and the Organisation 
for Economic Co-operation and Development (OECD) to 
support the implementation of the UN Recommendations. 
PART 1
INTRODUCTION 
AND BACKGROUND
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around delivering patient-centred services which would 
ultimately positively impact patient and population health 
outcomes. To achieve this transformation, an integrated 
and concerted multi-stakeholder effort is needed to build a 
capable and adaptable workforce. 
FIP, under the aegis of FIPEd, is committed to supporting all 
stakeholders in translating the Nanjing outcomes into actions, 
particularly the PWDGs. The PWDGs have been developed as a 
measurable, feasible and tangible means to activate and give 
purpose to the Global Vision. They will provide action-oriented 
workforce planning and ways of monitoring progress towards 
global achievement of the workforce vision.
Crucially, they will provide consistent structure for coherent 
and comprehensive national workforce development actions 
that are in line with global health workforce strategies. The 
PWDGs are highly aligned with the WHO Global Strategy for 
HRH, the UN Commission Recommendations and the WHO-ILO-
OECD Five Year Action Plan (Annex 2). By adopting the PWDGs, 
nations would be working towards implementing global 
health workforce development goals in the pharmaceutical 
context. 
As the education arm of FIP, FIPEd has pioneered in developing 
tools and resources intended to enable worldwide action to 
advance and transform the global pharmaceutical workforce 
through education. The tools, listed in Annex 3, are designed to 
be locally adaptable to meet the specific needs and priorities 
of the nation or region. FIP advocates for the consistent use 
of a needs-based approach to education, emphasizing the 
formation of linkages between pharmaceutical education 
with population health needs. The FIP "needs-based education" 
model supports the notion that pharmaceutical education 
should be locally determined, socially accountable, globally 
connected, and quality assured to meet the given health needs 
of communities (Figure 1.1).
Just as investing in the world’s health workforce is a global 
imperative, investing in its pharmaceutical workforce is also 
a priority. With the release of various global health workforce 
strategies and the adoption of a new roadmap for the 
pharmaceutical workforce, FIPEd is committed now more than 
ever to support the implementation of these development 
strategies on a national, regional and global level.
Following an extensive consensus-based consultation process, 
three milestone documents were adopted at the global 
conference. The documents are presented and described in a 
full report of FIP’s global conference, “Transforming pharmacy 
and pharmaceutical sciences education in the context of 
workforce development”, published in May 2017.6 The three 
principal outcomes are: 
1. A Global Vision for Education and Workforce that 
provides a description of the future directions of 
our profession and how education can support the 
progression of medicines science and practice. 
2. A set of Pharmaceutical Workforce Development Goals 
(PWDGs) which aim to facilitate national implementation 
of the Global Vision and roadmap through a series of 
measurable, feasible and tangible goals (listed in Annex 1).
3. A set of Statements on Pharmacy and Pharmaceutical 
Sciences Education ("the Nanjing Statements") 
that describe an envisioned future for progressive 
professional education, to enable the further 
enhancement of pharmaceutical education standards 
worldwide.
FIP set the roadmap to transform the global pharmaceutical 
workforce through education. The Global Vision, PWDGs and 
Nanjing Statements are intended to provide strategic support 
to member organisations in strengthening their capacity to 
develop education in the context of workforce development 
to ensure that optimal drug therapy-related patient care is 
delivered and health outcomes are improved. 
Moreover, drug expenditure and health-related costs are 
under close scrutiny by governments and the population in 
general, as patient demands and health needs have grown 
exponentially, accompanied by an increase in the number 
of new medicines and the indications for which they are 
used. Margins over the price of drugs have been decreasing 
as a result of governments’ efforts to contain increasing 
drug expenditure costs, and pharmaceutical professional 
associations and leadership bodies have been driving 
negotiations for payment for pharmaceutical services. 
However, pharmaceutical care is yet to become a part 
of everyday practice for most pharmacists, as it requires 
fundamental changes in practice, education and regulation – 
and these changes are still not occurring at the required pace.
Research has proven the value to patients and healthcare 
systems of a range of pharmaceutical services. Now that 
pharmacists have advocated for a wider scope of practice, 
the society will ultimately hold pharmacists accountable 
for delivering these expanded healthcare services. As the 
professional and economic future of pharmacy lies in the 
ability of the workforce to deliver quality care related to 
medicines use, it is imperative to invest in an education 
that would transform the workforce into competent health 
professionals prepared to fully transition from a product and 
dispensing-focused environment to a practice that revolves 
c  -   Pharmaceutical workforce refers to the whole of the pharmacy related 
workforce (e.g. registered pharmacist practitioners, pharmaceutical scientists, 
pharmacy technicians and other pharmacy support workforce cadres, pre-
service students/trainees) working in a diversity of settings (e.g. community, 
hospital, research and development, industry, military, regulatory, academia 
and other sectors) with a diversity of scope of practice.
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Figure 1.1: FIP Needs-based educational model.
1.3 What is the purpose of this report?
Research, development and evaluation mechanisms are 
integral to achieving the UN Recommendations and the 
tripartite Five Year Action Plan for human resourced for health. 
The high alignment of the PWDGs with these global strategies 
make research, development and evaluation strategies 
an equally important consideration for implementing the 
pharmaceutical workforce development agenda. 
In light of this, understanding the current global trends 
in research, development and evaluation and identifying 
knowledge gaps, drivers and opportunities for future work 
is clearly important. This report therefore aims to discuss 
and share global research, development and evaluation 
strategies to support member organisations in the 
effective implementation of the pharmaceutical workforce 
development roadmap.
In Part 2, global research, development and evaluation 
strategies collected from 21 countries around the world are 
presented; real examples of PWDG-linked national strategies, 
projects and initiatives are provided to enable stakeholders 
to adopt the PWDGs in their own context using practical and 
adaptable approaches and mechanisms from other countries.
Part 3 features expert briefs that summarise progress, 
highlight knowledge gaps and explore future research, 
development and evaluation agendas for a number of PWDG-
themed topics, including: academic capacity, workforce 
impact, leadership, and workforce intelligence. The briefs 
highlight priorities for future research activities to progress 
implementation towards the PWDGs. 
Part 4 is dedicated to discussing research and development 
in the context of technology-driven education, highlighting 
various important technological methods used in education, 
and the impact of developed tools and platforms on workforce 
development. 
A final summary of trends and call to action for stakeholders 
conclude the report in Part 5. 
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identify national priorities moving forward; this will assist 
in the development of global pharmacy education policy 
recommendations and further resources.
2.2 Method
Case study template questions were drafted and peer-
reviewed internally within FIPEd. The template was then 
sent to two contacts from member organisations to pilot the 
questions. Comments on clarity of the questions and response 
options available were received and changes were made 
accordingly. 
The case study template consisted of three main questions. 
The first requested authors to provide a summary of key 
strategic projects developed or under development in their 
country. The second question asked contributors to identify 
national strategies, projects or initiatives aligned with the 
PWDGs. The final question asked authors to identify key 
PWDGs that are priorities for the next five years. 
A call for case studies was sent to all FIP member organisations 
and FIPEd contact lists between April and June 2017. 
Reminders were sent twice and a total of 23 submissions 
spanning 21 countries were received. Table 2.1 lists the 21 
countries, grouping them by World Health Organization (WHO) 
region. All WHO regions are represented in the responses with 
the exception of South East Asia; the majority of the cases 
originate from Africa (n=7) and the Americas (n=6). Multiple 
submissions from the same country were merged. Responses 
were assessed, thematically grouped and presented 
descriptively.
Lead author: Lina R. Bader, FIPEd Project Coordinator 
and Researcher (lina@fip.org).
Co-authorsd: 
Argentina - Marcela Longhi, Alicia Merlo, Laura Raccagni, Maria 
Isabel Reinoso and, Jose Enrique Ruggieri; Australia - Bronwyn 
Clark, Ian Coombes, Michael Dooley, Andrew Matthews, Kristin 
Michaels, Debra Rowett and, Nick Shaw; Brazil - Zilamar Costa, 
Silvana Nair Leite, and Luciano Soares; Chile - Patricia Acuna-
Johnson, Rocio Alvarez, Silvia Bonilla, and Patricia Carreno; 
China - Suying Yan, Jiang Dechun and Liu Chen; Costa Rica - 
Beatriz Badilla, Adriana Figueroa, Lidiette Fonseca González, 
and Gustavo Sáenz García; Ghana - Rauf Audu, Daniel Danquah, 
Mahama Duwiejua, and Jonathan Martey; Great Britain - Chris 
John; Japan - Naoko Arakawa, Shigeo Yamamura; Kenya - 
Rakhi Karwa, Gabriel Kigen, Imran Manji, Monica Miller, Ellen 
Schellhase, and Tina Tran; Malaysia - Jamia Azdina Jamal, 
Benny Efendie, Mohamad Haniki Nik Mohamed, and Ramli 
Zainal; Namibia - Dan Kibuule, Tafadzwa Mangombe, Vulika 
Nangombe, and Timothy Rennie; Paraguay - Patricia Acosta, 
Gladys Mabel, and Zully Vera; Portugal - Luís Rhodes Baião, 
Margarida Caramona, Filipa A. Costa, and Bruno Sepodes; 
Singapore - Lita Chew, Wai Keung Chui, and Tuck Seng Wu; 
South Africa - Mariet Eksteen, Joggie Hattingh, Sarel Malan, 
Lorraine Osman; Uganda - Richard Adome, Edson Ereeta, 
Hussein Orla, and Kalidi Rajab; United Arab Emirates - Ola 
Ahdab and Dixon Thomas; United States of America - Shaun 
Gleason, Lucinda Maine, and Ruth Nemire; Zambia - Martin 
Kampamba, Machi Hampango, Jimmy Hangoma, and Lungwani 
Tyson Muungo; Zimbabwe - Isaac Magaya, and Tsitsi Monera-
Penduka. 
2.1 Introduction
Following on from the Global Conference on Pharmacy and 
Pharmaceutical Sciences Education, FIPEd is committed to 
support Member Organizations utilize the key outcomes to 
develop the global pharmaceutical workforce in the context of 
education and training. 
To this end, FIPEd has conducted a global call for case studies 
to identify and share examples of national-level research, 
development and evaluation strategies in pharmaceutical 
education and workforce development. In this report, we aim 
to highlight the alignment of national development projects 
with the PWDGs and better understand the various national 
policies and mechanisms in place, to assist FIP member 
organisations and all pharmacy stakeholders to transform 
their pharmaceutical workforce through implementing the 
PWDGs. 
The purpose of the case studies is to provide a global snapshot 
of how the PWDGs are aligned with national strategies on 
pharmaceutical education in different countries and 
PART 2
PROGRESS TOWARDS THE PHARMACEUTICAL 
WORKFORCE DEVELOPMENT GOALS (PWDGS)
d  -    A full list of co-authors affiliations is available in Annex 4.
Table 2.1: Case study respondent countries by WHO region.
WHO Region
Africa
Americas
Eastern 
Mediterranean
Europe
Western Pacific
Countries
Ghana; Kenya; Namibia; South 
Africa; Uganda; Zambia; Zimbabwe
Argentina; Brazil; Chile; Costa Rica; 
Paraguay; United States of America
United Arab Emirates
United Kingdom; Portugal
Australia; China; Japan; 
Malaysia; Singapore
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For example, PWDGs 3 (Quality assurance), 7 (Service provision) 
and 8 (Working with others) are among the most highly 
mapped across the 20 countries’ strategies. Conversely PWDGs 
10 (pharmaceutical workforce gender and diversity balance) 
and 11 (workforce impact and effect on health improvement) 
are among those least mapped in the reporting countries’ 
strategies.
2.3 Results and discussion
2.3.1 Summary of global strategies 
alignment with the PWDGs 
The case studies collected data on national-level research, 
development and/or evaluation strategies and projects 
mapped with the PWDGs. These included existing, under-
development or planned projects. While strategies were 
reported across all PWDG themes, the extent of global 
mapping varies across the goals. Figure 2.1 shows, for each 
PWDG, the total number of countries reporting a mapped 
strategy or project.     
  
Figure 2.1: PWDG mapping with country strategies spanning 21 countries. 
The level of PWDG-strategy alignment also varies across countries. 
Figure 2.2 summarises the reported alignment per country. It 
is important to acknowledge that, because case study authors 
report country information to the best of their knowledge, the 
potential inaccuracy of information is a real limitation.   
Figure 2.2: Strategies alignment with PWDGs per country.
For this reason, quantitative analysis of the data is best 
avoided. These numbers may, however, serve to provide as 
general indicators of the level of PWDG-strategies alignment. 
The following section describes the global trends in research, 
development and evaluation strategies per PWDG and 
identifies common and recurring themes.
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while experiential training has been fully integrated into the 
pharmacy programmes, the academic workforce’s current 
capacity to participate in this training programme is still 
suboptimal. In South Africa, strategies for academic capacity 
are reportedly underdeveloped, despite this being a critical 
area that requires urgent attention and priority-setting. 
Reported barriers include budgetary and resource constraints, 
and lack of strategies addressing the difficulties experienced 
in attracting and retaining suitably qualified academics. 
Strategy integration
Extensive national frameworks and policies are in place 
in Japan. The frameworks address the standards of core 
curricula, guidelines for undergraduate training, as well 
as a consultation programme for evaluating the quality of 
pharmacy graduates. A Vision document for pharmacists’ 
professional abilities and contributions to society in the 
future intends to provide a baseline of initial pharmaceutical 
education, lifelong learning, and specialist pharmacists based 
on expected roles of pharmacists in team-based healthcare in 
the future; this is intended to guide the development of robust 
national model curricula and career pathways.
The professional association and the regulator are both 
driving academic capacity strategies in the UK’s Great 
Britain. The Royal Pharmaceutical Society’s (RPS) Vision 
for Transforming the Pharmacy Workforce in Great Britain 
(“the RPS Vision”) emphasises the role of leadership 
development as part of capacity building, stipulating that all 
pharmacy students should have ready access to leaders in 
pharmaceutical science, policy and clinical practice to act as 
role models. In addition, the Society’s Roadmap to Advanced 
Practice supports the early professional development of 
pharmacy students and trainees. The UK regulator, the 
General Pharmaceutical Council, developed ‘Standards for 
the initial education and training of pharmacists’ for schools 
of pharmacy. The integration of clinical placements with the 
undergraduate pharmacy programme is also being evaluated 
for enhancing the academic capacity and training experience.
It is interesting to note that in China, there is variance in 
the form of entry-level education between universities. 
Some pharmacy schools offer entry-level degrees with a 
pharmaceutical sciences focus, and others teach programmes 
a clinical practice focus. Other universities opted for a 
combined track that provides a general education in both 
areas. 
Impact of capacity building
Kenya’s Diploma and Internship programmes facilitate needs-
based capacity building by targeting early career pharmacists. 
These programmes are specifically aimed at educating 
Kenyan pharmacists on how to advance clinical pharmacy by 
using local care programmes. By implementing the Diploma 
program, Moi Teaching and Referral Hospital has increased 
2.3.2 Case studies and global trends 
in research, development 
and evaluation strategies
PWDG 1: Academic capacity
Focus on the academic workforce
For academic capacity, a number of the strategies reported a 
strong focus on the academic workforce. For example, Costa 
Rica has put in place strategies targeting the improvement 
of the teaching process through congresses, meetings, 
workshops and professional development opportunities. The 
latter can be exemplified by the University of Costa Rica’s five-
year post-graduate education plan for its faculty members. The 
University of Medical Sciences has also put in place strategies 
to increase retention and recruitment of full-time teaching staff.
Governmental scholarship schemes in Malaysia allow 
practicing pharmacists and academics to further their studies 
(Master’s and PhD degrees) in areas such as clinical pharmacy, 
social and administrative pharmacy and the pharmaceutical 
sciences. In addition, mechanisms to encourage the 
engagement of practicing pharmacists in research are 
reported. Research weeks and conferences are organized at 
state and national levels; and, increasingly, pharmacists are 
joining research teams in clinical research centres across   
the nation. 
In Zambia, national-level initiatives to develop research in 
both the academic workforce and student body are reported. 
Academics are encouraged to participate in collaborative 
national research projects, and arrangements are in place 
through organised student research projects.
Regular meetings promoted by Brazil’s Federal Council of 
Pharmacy gather clinical educators to share best practice 
experiences and methods. Pharmacy educators are also 
engaged in governmental projects of workforce development 
for the public health system, such as the inter-professional 
Residency Program. These projects are intended to enhance 
the institutional capacity to offer professional training and 
increase engagement between the educational sector and 
the health system. Academics and students have also been 
engaging in discussions with professional organizations to 
formulate new proposals for pharmaceutical educational 
regulations, such as the new Pharmaceutical Education 
Guideline. 
Some countries reported challenges faced with regards to 
developing the academic workforce. Ghana reported that 
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the number of clinically trained pharmacists from 2 in 2011 to 
13 in 2017 with a potential impact on more than 7500 patients 
annually. This increase will further support the growth of 
this programme and the experiential opportunities in local 
practice sites provided to future students. The development of 
this programme is also helping to establish Moi Teaching and 
Referral Hospital as a Centre of Excellence in Clinical Pharmacy 
in Kenya.
Academic capacity and national higher education policies
Paraguay’s National Agency for the Evaluation and 
Accreditation of Higher Education established a national 
profile of pharmaceutical services, which describes the skills 
and attributes that students are expected to have upon 
graduation. It is an essential reference used for curricular 
design and review, teaching management and for the 
evaluation and accreditation purposes. Pharmaceutical 
education standards in the United Arab Emirates also largely 
rely on national higher education and accreditation standards.
 
Multi-sectoral engagement
In Singapore, a single pharmacy education institution exists at 
the National University of Singapore (NUS). This provides room 
for high engagement between the school, the pharmaceutical 
body and the health ministry. The three bodies work closely 
together on needs-based curricular development and 
ensuring that graduates have the foundational knowledge 
and skills needed. The Ministry of Health invites senior faculty 
members from NUS’s pharmacy school to participate in 
national strategic planning events and to facilitate dialogue 
among policy makers, educators and practitioners. Multi-
stakeholder engagement is evidenced in Zimbabwe as well. 
The Zimbabwean Pharmacists’ Council plays a key role in the 
curricular review for the University of Zimbabwe. Similarly, 
members from the University’s academic faculty as well as the 
national higher education agency are key stakeholders in the 
Council. 
Portugal’s Pharmaceutical Society established a Commission 
that is charged, among many tasks, with collaborating in the 
development of the professional and scientific education 
plan of pharmacists. This collaboration is largely done with 
the national higher education accreditation body. Namibia 
also reports that there is engagement between academic 
institutions and stakeholders in government, industry, and 
regulation to develop new educational programmes.
Argentina’s Pharmaceutical Federation set up a National 
Committee for Certification and Pharmaceutical 
Recertification that aims to assess the skills, behaviours and 
attitudes of pharmacists. While certification is not mandatory, 
it is a considered a formal, public recognition of the education 
and training received by pharmacists, bridging between 
education and practice.
PWDG 2: Foundation training and 
early career development
Structured and competency-based training frameworks
Some countries describe structured and competency-based 
training frameworks that underlie foundation training 
and early career development of the pharmaceutical 
workforce. Australia, for instance, describes a Hospital 
Pharmacy Residency Programme where experiential learning 
with structured feedback is critical for newly registered 
professionals to consolidate their formal academic education 
and apply this knowledge in real and complex workplace 
settings. In 2017, The Society of Hospital Pharmacists of 
Australia introduced a national, structured, and formalised 
the Residency Programme for pharmacists in their foundation 
years, or for pharmacists entering hospital practice but with 
experience in other practice settings. Through the two-year 
programme, residents rotate through a diverse programme 
curriculum, ensuring they gain the skills and knowledge 
necessary for competent general level pharmacists. 
Evaluation, feedback, and reflection are integral components 
of the programme. 
Singapore established a national competency framework 
for entry to practice pharmacists. It also revised the national 
pre-registration training model into 4 rotations of 3 months 
each; with 2 essential rotations in acute care and community 
care and another 2 elective rotations that can be selected 
from regulatory agency, pharmaceutical company, or specialty 
institutions. First year post-graduation, there is a Pharmacy 
Residency (PGY1) training of 12 months to be completed.
The Pharmacist’s Council of Zimbabwe has published 
comprehensive guidelines for pre-registration training for the 
pharmaceutical workforce including pharmacy technicians. 
The guidelines for pharmacists, for example, include checklists 
and logbooks for expected competencies. These competencies 
are aligned with the national ‘Professional Competency 
Statements For Entry Level Pharmacy License Applicants’. In 
Ghana, all newly qualified pharmacists are registered onto 
a provisional register of pharmacists until after successful 
completion of a mandatory 12-month post registration training.
A nationwide 1-year pre-registration programme is compulsory 
for a pharmacy graduate to become a registered pharmacist 
in Malaysia. This pre-registration programme can be done 
in premises approved by the Ministry of Health (MoH). The 
Pharmaceutical services division of MoH publishes the 
guidelines for the pre-registration programme and supervises 
its implementation. At the completion of the programme, 
the interns must submit their portfolios (log-books) and 
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be assessed by a team of preceptors. All candidates must 
also pass the forensic (pharmacy law and regulatory) exam. 
Following the completion of the pre-registration training, 
pharmacists are required to continue working in accredited 
pharmacy premises in order to complete their registration 
process. This is called “1 year compulsory service” and is 
intended to ensure that early career pharmacists gain 
sufficient experience before becoming a full-fledged 
pharmacist who can work independently. 
Linkages with continuing professional development
It is interesting to note that some countries reported on 
their continuing professional development (CPD) strategies 
as demonstration of progress towards PWDG2: Foundation 
training and early career development – illustrating the 
importance of CPD programmes in supporting the early career 
development of the pharmaceutical workforce. Costa Rica, for 
example, reported how one national university, the University 
of Costa Rica, developed a continuing education programme 
for its pharmacy faculty members to support them throughout 
their career progression. The University of Medical Sciences, 
also in Costa Rica, established a Centre for the Development 
of Pharmaceutical Initiatives (CEDIFAR), which supports the 
development of continuing education and the development of 
advanced education programmes.
The United Arab Emirates demonstrates how this PWDG 
is being achieved through two national strategies. One is 
through a government-led CPD programme for the country’s 
health workforce, including pharmacists. The programme 
offers a comprehensive array of CPD opportunities (e.g. 
accredited events and online resources). Additionally, the 
National Strategy for Innovation calls for planning innovation-
nurturing initiatives in both education and research, which 
includes designing effective internship programmes for health 
workers training and early career development. 
Supporting transition to advanced practice
In Great Britain, the RPS Vision stipulates that all newly 
qualified pharmacists will have access to foundation 
support, training and development to enable and assure 
their professional development during their early career. In 
addition, the RPS Roadmap to Advanced Practice and the RPS 
Foundation Programme provide a structure for professional 
development for new pharmacists – those in their first 1000 
days of practice. Principles for Foundation training are 
aligned to the Faculty (professional recognition programme 
for advanced and specialist pharmacists), thereby facilitating 
seamless transition towards advanced practice. Pharmacy 
graduates are required to complete a 52-week pre-registration 
training regulated by the General Pharmaceutical Council. The 
Council set out outcomes expected from trainee pharmacists 
in ‘Future Pharmacists: standards for initial education and 
training of pharmacists’. The Council also oversees the training 
of pharmacy technicians. 
Integrated PWDG2 strategies that support transition into 
advanced practices is also reported in Australia, where the 
Hospital Pharmacy Residency Programme (described earlier 
under PWDG1) comprises a consistent set of competency 
targets designed for residents to achieve performance against 
the Australian Advanced Pharmacy Practice Framework (APPF), 
at Advanced- Stage 1 (transition level) by the end of their 
residency, and then continue their professional development 
pathway aligned with the APPF. 
While China did not report having a structured advanced 
training framework that pharmacists can transition into 
from early career, the country does have offer post-licensing 
‘training’ opportunities for new pharmacists. For example, in 
Beijing, there is a system in place for early career pharmacists 
to train for 5 years; some pharmacists train to become clinical 
pharmacists during that time.
Strategy development through international collaborations
Japan’s primary pharmaceutical association (JPA) is working 
closely with the RPS in the UK on a Collaborative Programme 
that aims to develop foundation-level competency 
frameworks for pharmacists in Japan based on validated 
and utilized frameworks in Great Britain. This provides 
opportunities to develop a synergetic professional recognition 
model for pharmacists between the UK and Japan. In addition, 
the a pharmacy Vision statement in Japan provides a baseline 
of initial pharmaceutical education, lifelong learning, and 
specialist pharmacists based on expected roles of pharmacists 
in team-based healthcare in the future. This is intended to 
enable smooth transitional pathways for initial to early career 
development of pharmacists. 
Needs-based programmes to serve the local population
In Kenya, a pre-registration Clinical Pharmacy Internship 
Programme and a post-registration Clinical Pharmacy Diploma 
Programme are aimed at building foundational infrastructure 
and also paving the way for more developed post-graduate 
training programmes. Participation in both programmes 
is intended to increase involvement in clinical pharmacy 
activities to help participants develop first-hand knowledge 
of how to provide clinical care services. Interns and Diploma 
students are partnered with currently practicing Kenyan 
clinical pharmacists to provide career path mentorship and 
guidance on how to build further clinical pharmacy care 
programmes across Kenya. 
Not unlike Kenya, South Africa makes it mandatory for the 
first year post-internship to be spent performing community 
service. In general, the principle is that these young 
pharmacists should work in a public sector facility in an 
underserviced rural area. The new pharmacist is sometimes 
the first pharmacist appointed to a facility, and is aslo often 
the only pharmacist employed in the facility. The programme 
has, however, encountered difficulties because of the lack of 
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funded posts in the areas that need services the most. The 
National Department of Health has therefore reviewed the 
situation and is now entering into agreement with private 
sector pharmacies. There is no programme in place for 
foundation training at this stage.
Analysing pharmaceutical services and needs first
Paraguay conducted an in-depth analysis of pharmaceutical 
career progression at the national and regional levels. As a 
result, the professional profile for pharmacists in Paraguay 
was developed to meet the demands of society and to 
establish the professional skills required to face the multiple 
health service challenges. 
Focus on the pharmaceutical industry
Zambia reports that training and early career development 
is highly linked with demonstrating competence in the 
industry sector. A wide range of skills are important to gain 
during the primary and advanced training of pharmaceutical 
personnel. These skills include pharmaceutical technological 
and engineering techniques in pharmaceuticals production 
process knowledge such as product quality control and 
monitoring, in-process and end-product quality control 
& monitoring, and drug strategic storage conditions and 
techniques. 
In Namibia, the in-country training of pharmacists and 
pharmacy technicians not only works towards developing 
the workforce, but also reportedly stimulates the economy 
towards industrialization.
PWDG 3: Quality assurance 
Pharmacy quality assurance changes linked to broader health 
workforce planning
The Australian Pharmacy Council (APC) is the independent 
Accreditation Authority for pharmacy education and training 
in Australia. APC plays a key role in protecting the public 
safety by ensuring high standards of pharmacy education, by 
accrediting and monitoring education programmes, assessing 
overseas trained practitioners and conducting examinations 
on behalf of the Pharmacy Board of Australia. Australia’s 
accreditation system for registered health practitioners is 
undergoing an Independent Review of Accreditation Systems 
within the National Registration and Accreditation Scheme 
for health professions. The focus of the Review is threefold: 
to propose improvements to the system within the existing 
framework; to ensure the relevance and responsiveness of 
health education; and to ask the broader question of ‘how can 
education and training, and its accreditation, help create the 
workforce that Australia needs, both now and in the future.’ 
Should Health Ministers determine that an amalgamated 
single accreditation authority for all regulated health 
professions be implemented, the APC profession-specific 
regulatory activities may be lost. The Australian pharmacy 
profession believes it is important that, to ensure public safety 
in relation to the registration and accreditation standards of 
pharmacy, the profession does not lose control of the high 
quality and standards that have been achieved to date by the 
APC. The PWDGs and the Nanjing Statements have reportedly 
assisted the Australian pharmacy profession in this regard.
National higher education quality assurance systems
Brazil has a public, transparent and well-structured system 
to evaluate the quality of pharmacy education and to assess 
universities capacities to offer pharmacy courses. This 
system includes in loco evaluation of the infrastructure of 
the university and the school of pharmacy, and students´ 
performance exams. The National Health Council (that 
represents government and society in public health 
governance) is planning to evaluate the health needs before 
allowing the establishment of new schools of pharmacy. 
Accreditation of pharmacy courses in Argentina is based on 
the standards of the National Commission of Evaluation and 
University Accreditation. Courses that are not accredited 
by the Commission cannot offer to teach pharmacy. 
Similarly, Costa Rica’s pharmacy education programmes 
are accountable to the standards of the country’s National 
Accreditation System.
The quality assurance mechanism of pharmaceutical 
education in Japan is also overseen at the national level by 
the education ministry’s accreditation mechanisms. The 
evaluation and accreditation process allows for engagement 
with higher education institutions and academic leaders to 
support national workforce development agendas.
Kenya’s Clinical Pharmacy Internship Programme and 
Clinical Pharmacy Diploma Programme were developed 
based on national standards and the Diploma programme 
has received accreditation by national regulatory agencies. 
National standards and participant feedback are used to 
make continued changes to these programmes to ensure they 
address the professional skills expected by graduates. 
Following the recent development of quality assurance 
systems, namely those in the European area, the government 
in Portugal established the Agency for Assessment and 
Accreditation of Higher Education (A3ES) with the purpose of 
promoting and ensuring the quality of higher education. A3ES 
conducted a recent national evaluation of pharmaceutical 
sciences degrees across all schools of pharmacy. 
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This evaluation comprises a number of factors: the quality of 
teaching, considering the syllabus and the curricular units, the 
laboratory facilities, the physical structure of the institutions 
and the qualification of the teaching staff, to name a few. The 
standards are established according to the European Union. A 
report will be issued describing the Agency’s decisions.
In the United Arab Emirates, the Commission for Academic 
Accreditation (CAA) of the Ministry of Education conducts a 
programme of licensure of institutions of higher education 
and accreditation for each of their academic programmes –
including pharmacy degrees. The CAA published a new edition 
of the Standards for Licensure and Accreditation in 2011 where 
it refined its existing standards and procedures to ensure that 
newly established institutions and programmes, as well as 
existing ones, meet high levels of quality.
Pharmacy-specific quality standards 
In Chile, the undergraduate pharmacy academic programme 
was one of the first to voluntarily undergo evaluation of its 
quality. In 2000, an advisory committee made up of members 
representing the National Accreditation Commission, 
pharmacists from representative areas of professional practice, 
and academic representatives of public pharmacy schools at 
that time, was responsible for establishing the first Criteria 
and Standards for the evaluation of pharmacy schools. Its 
work was guided by recommendations of the Pan American 
Health Organization and the World Health Organization (PAHO/
WHO) regarding the content of the curriculum. Since then, 
the accreditation criteria have not been updated, in spite of 
significant changes in Chile regarding the more active role of the 
pharmacists in the society (e.g. National policy of medications 
on the Health Reform), and availability of key documents on 
quality assurance of pharmaceutical education at a regional 
level (e.g. Accreditation Standards for Pharmacy programmes 
in Latin America: A proposal) and global level (e.g. Quality 
Assurance of Pharmacy Education: the FIP Global Framework).
Another ongoing development in Chile demonstrates the 
intersection of academic research and national strategy 
development. It describes a large-scale research project 
undertaken by the pharmacy school at Universidad de 
Valparaíso; the project aims to re-examine accreditation criteria 
and standards for Pharmacy programmes in Chile, by comparing 
the quality assessment model of Chile's pharmaceutical 
education programmes with regional and global reference 
frameworks. The project is titled “A comparative study of the 
quality assessment model for Chilean pharmaceutical education 
programmes, with both regional and global frameworks, for 
an up to date proposal.” The study is composed of 5 stages: 
selection of reference documents, analysis of reference 
documents, validation of the analysis carried out, proposal and 
dissemination. 
The results are expected to produce a new document for 
assessing quality assurance of pharmaceutical education at a 
national level and would become a milestone for Chilean higher 
education; it may also serve as an example for global pharmacy 
schools wishing to conduct research to evaluate accreditation 
standards for pharmacy education.
The General Pharmaceutical Council is responsible for setting 
and regulating the education and training requirements for 
pharmacists and pharmacy technicians in Great Britain. In 
addition, the professional leadership body, the RPS Vision 
states that “Evidence-based quality indicators are essential 
in the education and training of pharmacists to ensure all 
involved continually strive for excellence”. In addition, the 
quality of the RPS Foundation Programme and the Faculty is 
overseen by a strategic Board with three quality assurance 
panels for accreditation, curricula and credentialing. 
Paraguay’s National Advisory Commission established 
standards for basic pharmacy curricular contents, practical 
training, as well as the professional activities reserved to those 
who obtain the title of Pharmacist and/or Pharmaceutical 
Chemist in order to harmonize their training at national and 
regional level.
South Africa’s quality assurance mechanism is achieved 
by regular monitoring of educational institutions by the 
Pharmacy Council, and by the periodic development of the 
pharmacy qualification. During the development process, the 
Council engages in both narrow and wide consultation within 
the profession.
Joint accreditation process between multiple sectors
Malaysia reported having a joint accreditation of pharmacy 
programmes (especially for undergraduate programmes) by 
the Malaysian Qualification Agency (MQA) and Pharmacy Board 
of Malaysia (PBM). The accreditation is based on standards 
developed jointly by the MQA and PBM together. 
In Namibia, all educational programmes as well as facilities 
in Higher Education Institutions undergo a rigorous process 
of quality assurance by an in-house quality assurance unit, 
a health regulator (Health Professions Councils of Namibia), 
a national qualifications registration body (Namibia 
Qualifications Authority), and an educational regulator 
(National Council for Higher Education).
Zimbabwe’s pharmacy council inspects training institutions 
every 3 years to ensure quality of pharmacy education. 
The Ministry of Health and Child Care and the Taskforce on 
Quality Assurance for Pharmaceutical Development engage 
with members from the Schools of Pharmacy and pharmacy 
technician colleges to ensure quality of pharmacy education.
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Quality assurance linked to student performance and 
registration requirements
In Ghana, internal quality assurance mechanisms in pharmacy 
schools regularly assess quality through both theory and oral 
examinations. Final year students take a mandatory end of 
programme examination and successful candidates undertake 
a 12-month pre-registration internship before sitting for 
the Ghana Pharmacy Professional Qualifying Examination. 
Successful candidates become eligible to be registered onto 
the provisional register of pharmacists. Ghana also reports 
that there is strong collaboration between the Pharmacy 
Council and the National Accreditation Board, but that self-
assessment systems require further strengthening in the 
pharmacy training institutions.
China reported how licensing examinations are used as a 
form of quality assurance. All Beijing pharmacists who have 
completed their training (which ranges in length depending 
on area of practice) would have to successfully pass two 
examinations to ensure they are prepared to practice as 
pharmacists. 
Quality assurance of lifelong learning
While the quality assurance of foundational education in 
Japan is regulated by the education ministry, the quality 
assurance of pharmacy lifelong learning programmes 
is overseen by the Council on Pharmacists credentials 
which provides evaluation criteria to maintain the quality 
of pharmaceutical education in Japan. The evaluation 
and accreditation process engages with lifelong learning 
programme providers and specialist pharmacist training 
providers to support national workforce development 
agendas.
The United Arab Emirates Ministry of Health, together with 
local health authorities, accredit continuing professional 
development programmes.
Quality assurance mechanisms under development
Singapore is in the process of Establishing National Standards 
for Undergraduate Pharmacy Education and Training; and 
Zambia reports that establishing a quality assurance system 
would provide the pharmaceutical trainees with the necessary 
skills development pathways.
PWDG 4: Advanced and specialist expert 
development 
National professional recognition models and policies
In Great Britain, the RPS Roadmap to Advanced Practice 
outlines three principal career pathways (Pre-Foundation, 
Foundation and Faculty) for pharmacists and pharmaceutical 
scientists and describes the available support and development 
at different stages of practice. The Roadmap describes the 
principles of the Faculty, a professional recognition programme 
for advancement as a generalist and specialist. Furthermore 
the RPS Knowledge Interface Tool enables pharmacists to 
access validated knowledge components for specialist career 
pathways. The RPS Vision also describes how “Pharmacists will 
have demonstrated their skills, knowledge, and practice using 
RPS standards and professional development frameworks in 
all care settings and for the ultimate benefit for patients”. In 
addition to the advanced generalism model offered through the 
Faculty, pharmacists in Great Britain can become independent 
prescribers – a process regulated by the General Pharmaceutical 
Council. 
Japan’s Vision document provides a baseline of initial 
pharmaceutical education, lifelong learning, and as well as 
specialist pharmacists based on expected roles of pharmacists 
in team-based healthcare in the future. This enables seamless 
transition from initial to early career levels, and onto 
advanced and specialist expert development. In addition, the 
collaboration between the Japan Pharmaceutical Association 
and the RPS, aims to enhance CPD support systems for Japanese 
pharmacists; the project will develop an advanced-level 
competency framework using existing frameworks 
in the UK. 
Portugal’s Pharmaceutical Society regulates five formal 
pharmaceutical specialisations: hospital pharmacy, 
pharmaceutical industry, regulatory affairs, clinical analysis 
and human genetics. All these specialisations were created 
under the advice of the Society’s Council for Qualification and 
Admission (CQA) and further developed by each of the Specialist 
Boards respectively. Each candidate must submit evidence 
of 4-5 years of practice, with training in different areas of the 
specialisation, comply with the requirements set out by each 
specialisation and successfully pass an oral and/or written 
exam. There is still no specialisation in Community Pharmacy 
but it is being strongly considered for the near future. 
Singapore established national competency standards for 
pharmacists in advanced practice, national pharmacy residency 
programme (PGY2) for specialty areas of pharmacotherapy; 
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and a national register for specialist pharmacists (in areas of 
cardiology, infectious diseases, psychiatry, oncology, geriatric 
care; with future expansion in paediatric care and intensive 
care).
Strategies for overcoming barriers to implementation
Australia has reported on the progress made in the 
development and implementation of a practitioner 
development pathway for pharmacye. The Australian Advanced 
Pharmacy Practice Framework (APPF) was published in 
October 2012, and the Australian Pharmacy Council (APC) was 
endorsed in December 2013 as the independent entity being 
responsible for the credentialing of advanced practitioners 
in Australia. In 2014, APC began a credentialing of advanced 
practice pharmacists pilot programme, to evaluate the 
assessment processes prior to full implementation of the 
programme. Based on the findings of the pilot, APC began 
a National Credentialing of Advanced Practice Pharmacists 
programme in March 2016. Due to sustainability issues with 
the model, the credentialing programme ended in October 
2016. In February 2017, the profession recognised that 
formalised advanced pharmacy practice was needed now 
more than ever for pharmacists to be able to competently 
manage increasingly complex patient services and demanding 
healthcare needsf. An Advanced Practice ‘from pilot to 
permanent’ Think Tank, was held amongst representatives 
from all key pharmacy organisations in Australia with a 
collective commitment to developing a central operational 
mechanism to advance the national pharmaceutical 
workforce, in turn strengthening medicines management 
and delivering optimal health outcomes to Australians. Work 
continues between organisations to develop this mechanism. 
In addition, progress towards transnational parity of advanced 
pharmacy practice has taken a significant step forward with 
the signing of an agreement between the RPS of Great Britain 
and the Society of Hospital Pharmacists of Australia (SHPA). The 
new agreement will see the RPS and the SHPA collaborating to 
deliver quality-assured education, training and development 
opportunities mapped to pharmacist career stages in the 
UK and Australia, including mutually accredited, two-year 
advanced practice specialist residencies for pharmacists 
across a range of practice areasg.
Advanced and specialist pathways under development
In Brazil, the process to define the regulatory framework 
for qualifications of pharmacists specialised in advanced 
professional practices in various sectors is under development 
in the Federal Council of Pharmacy (professional regulatory 
organization), involving the establishment of educational 
requirements and delimitation of professional competencies. 
Some examples include the areas of homeopathy, 
anthroposophy, oncology, clinical cytology, 
and pharmaceutical prescription.
Malaysia is currently working on developing a system 
for advanced practice and specialisation. Formalising 
specialisation for pharmacists, as well as credentialing and 
privileging mechanisms for advanced practice, are being 
led by the Pharmaceutical Services Division of the Ministry 
of Health (MoH). In the meantime, the MoH, the Malaysian 
pharmaceutical association and the Academy 
of Pharmacy encourage pharmacists to obtain certification 
from the Board of Pharmacy Specialties (BPS). Currently, 
pharmacists in Malaysia can lead diseases-specific clinics; 
these include management of asthma, diabetes mellitus, 
hypertension, HIV/AIDS and specific medicines and services 
such as anticoagulants, methadone, smoking cessation, 
etc. Pharmacists need to undergo adequate training and 
certification as the providers of these specialised services. 
Although the introduction of the new specialities has 
not taken place in South Africa yet, there are currently 
infrastructures in place for the existing specialities. In 
addition, there is an accredited programme in Primary Care 
Drug Therapy that can be used to obtain a permit which 
authorises pharmacists to initiate therapy in accordance with 
strict treatment guidelines for primary healthcare.
Zimbabwe’s pharmaceutical council is working on developing 
a framework for recognition of advanced and specialist 
pharmacy personnel. Soon, Master’s degrees in regulatory 
pharmacy, toxicology and traditional medicine will be offered 
by the University of Zimbabwe. 
Argentina reports having established a National Committee 
for Certification and Recertification of pharmacists; while it is 
not directly linked to advancing practice and/or specialisation 
nor it is mandatory for pharmacists, it does provide a working 
pathway for professional recognition that could in the 
future provide a platform for advanced and/or specialised 
recognition. 
Postgraduate education and training for advanced and 
specialist practice
In some countries, higher education is linked to development 
strategies for advanced and/or specialised practice. Costa 
Rica reported progress by describing the specialist master’s 
degree as a pathway to advancing clinical pharmacy practice. 
The University of Costa Rica is developing a master's degree in 
e  -  Galbraith K, Coombes, I, Matthews A, Rowett D, Bader L, Bates I. Advanced 
pharmacy practice: Aligning national action with global targets. Journal of 
Pharmacy Practice and Research, 2017. 47(2):131-135. Available from: 10.1002/
jppr.1333
f  -  The Society of Hospital Pharmacist of Australia (Media Release). From pilot 
to practice: Advancing Australian pharmacy workforce confirmed as priority. 
Melbourne: The Society of Hospital Pharmacists of Australia, 2017. Available 
from: www.shpa.org.au/news/from-pilot-to-practice-advancing-australian-
pharmacy-workforce-confirmed-as-priority
f  -  The Society of Hospital Pharmacist of Australia (Media Release). Historic 
partnership heralds new international advanced pharmacy practice model. 
Melbourne: The Society of Hospital Pharmacists of Australia; 26 May 2017. 
Available from: www.shpa.org.au/news/historic-partnership-heralds-new-
international-advanced-pharmacy-practice-model-0
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hospital pharmacy with an emphasis on clinical pharmacy, and 
the University of Medical Sciences offers a master's degree in 
Clinical Pharmacy too. 
Similarly, Ghana reported that pharmacists have access 
to university-run fellowship programmes leading to 
specialisation in various areas of practice. In addition, the 
pharmacy council makes note of additional qualifications 
obtained by pharmacists in the register of pharmacists.
There is currently no formalised recognition system for 
advanced and/or specialist pharmacists in Namibia. However, 
it is intended that various programmes will provide stepping-
stones towards specialisation in various fields. These include: 
intake of Masters and PhD level research training since 2013; 
launch of a work-based post-graduate clinical programme 
(Master of Pharmacy – Clinical) in 2016 for pharmacists; 
piloting of a pre-registration internship training support 
programme for graduates; development of a taught post-
graduate programme in industry & regulation (Master of 
Pharmacy) intended to launch in 2018; and development of 
a taught post-graduate programme in veterinary pharmacy 
(PG Diploma in Veterinary Pharmacy) intended to launch in 
2018/19.
Paraguay reports that recent reviews in curricula have been 
made to develop problem-solving, communication and 
leadership skills in graduates –allowing them to take on more 
complex roles in practice and preparing for the delivery of 
advanced services. 
In Zambia’s industry-focused pharmacy profession, advanced 
training in pharmacy involves conducting research; developing 
a national strategic plan will make it easier to generate further 
research and outcomes that can benefit the field.
While formalised advanced and specialised competency 
frameworks have not been reported to be in China, the 
country’s hospitals are equipped with a training system and 
the infrastructure to support the transition of pharmacists 
into advanced and specialised areas of clinical practice. 
International collaborations and partnerships
Residency programmes are available for health professionals 
through government-led initiatives in the United Arab 
Emirates. Pharmacists have access to advanced training 
opportunities mainly through the network of public-private 
partnerships and private international healthcare facilities 
(e.g. pharmacy residency programmes through Cleveland 
Clinic, USA for the pharmacists in the Cleveland Clinic, Abu 
Dhabi). Pharmacists are encouraged to become certified by the 
US BPS, especially in Nutrition Support Pharmacy. Many Board-
certified pharmacotherapy specialists are already working in 
hospitals. International collaboration is a key national strategy 
for advancement of pharmaceutical workforce.
PWDG 5: Competency development  
Competency development frameworks and tools
Two tools have been developed in Australia: (1) the Clinical 
Competency Assessment Tool and (2) a new national 
competency standards framework. Australia developed the 
Clinical Competency Assessment Tool (shpaclinCAT) using 
CoDEG’s General Level Framework (GLF) for Pharmacist 
Development in General Pharmacy Practice as the basis. The 
shpaclinCAT was the first clinical competency assessment 
tool described for Australian pharmacists. clinCAT was made 
possible through a Memorandum of Understanding between 
SHPA, Monash University and the UK Competency Development 
and Evaluation Group (CoDEG). clinCAT aims to support 
pharmacists’ professional development in all settings through 
structured evaluation. 
A new national competency standards framework for Australia 
was released in 2017h. The framework was developed by 
the Pharmacy Practitioner Development Committee (PPDC) 
which has representatives from all 11 pharmacy member 
organisations. This revision of the 2010 standards was 
conducted as part of a regular cycle of reviews to ensure the 
profession’s competency standards framework is consistent 
with contemporary pharmacist practice and the interests 
of public safety, and reflects future needs of the Australian 
healthcare system. The new Competency Standards framework 
consists of five domains covering (1) Professionalism and 
ethics, (2) Communication and collaboration, (3) Medicines 
management and patient care, (4) Leadership and management 
and (5) Education and research. This new edition has integrated 
the existing Advanced Pharmacy Practice Framework (APPF) 
to now produce a single competency standards framework to 
truly reflect the continuum of practitioner development.
In Ghana, competency standards for all stages of professional 
careers including leadership development frameworks for 
pharmacists have been developed by the country's pharmacy 
Council. The council is working to ensure alignment of training 
curricula with these competencies.
h  -  Pharmacy Practitioner Development Committee. National competency 
standards framework for pharmacists in Australia 2016. Canberra; 31 
May 2017. Available from: http://advancedpharmacypractice.com.au/
download/resources/5202%20National%20Competency%20Standards%20
Framework%20for%20Pharmacists%20in%20Australia%20_FINAL.
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Great Britain’s RPS developed the Foundation Pharmacy 
Framework (FPF) and the Advanced Pharmacy Framework (APF) 
(developed from evidence based development frameworks); 
the two frameworks underpin the Foundation Programme 
and Faculty, respectively. The frameworks are applicable to 
all sectors and settings of pharmacy practice, and align well 
to global competency frameworks. Leadership competencies 
form one of the six clusters in the APF.
Paraguay’s National Agency for the Evaluation and 
Accreditation of Higher Education (ANEAES) established a 
national profile of the pharmacist, with the support of the 
Career Advisory Commission. The document is the result of 
collaborative work among a group of national experts and 
representative bodies.
Singapore has also developed two frameworks describing 
(1) national competency standards for entry-to-practice 
pharmacists and (2) national competency standards for 
advanced practice pharmacists. 
Competency frameworks under development
Japan’s collaborative project with Great Britain’s RPS is 
expected to result in the productions of foundation- and 
advanced-level competency frameworks for pharmacists in 
Japan based on validated and utilized frameworks in Great 
Britain. 
Competency development is a work-in-progress project in 
Namibia. Currently, competencies are described for all taught 
cadres but scopes of practice are not yet properly described.
Portugal’s Pharmaceutical Society Boards of Specialisation 
and professional groups are in the process of developing 
competency frameworks for various areas of the 
specialisation: community pharmacy; hospital pharmacy; 
regulatory affairs; and pharmaceutical industry. These will 
undergo review by the Society’s Council for Qualification and 
Admission (CQA). There are also areas where “recognition of 
training” needs to be sought to deliver certain services (e.g. 
administration of vaccines and injectable medicines). Other 
areas of “recognition of training” have been drafted, but are 
still pending formal approval (e.g. dispensing of antiretroviral 
therapy in community pharmacies).
Progress has been made in South Africa in their development 
process. The country reported that the development of the 
competency standards is progressing well. Competencies have 
been identified for all stages of professional practice.
The United Arab Emirates also reported that the regulatory 
agencies overseeing education, training and practice are keen 
on developing competency standards. Currently, pharmacy 
graduates must first pass a ‘competency exam’ before 
undergoing compulsory training of 6 months to 2 years in 
length in order to become licensed practitioners. 
The United States of America, on the other hand, describes 
progress made towards this PWDG through the development 
of Entrustable Professional Activities (EPAs). The rationale for 
development of the first set of EPAs for pharmacy graduates 
was to provide clarity regarding the knowledge, skills and 
abilities of professionals completing entry-to-practice education 
at the doctoral level (PharmD). This enables strong curricular 
assessment and implementation, enhanced learner assessment 
opportunities, and provides tools to communicate to key 
stakeholders (e.g., patients, employers, policymakers) exactly 
what graduates are prepared to do.
Competency standards to guide pharmaceutical education and 
training
In Costa Rica, the professional association has established 
the general competencies of the Costa Rican pharmacist, the 
professional academic profile and the specific competencies 
based on the principles of Primary Health Care.
An initial competency framework for pharmacy graduates 
in Malaysia has been included in the standard for pharmacy 
education providers in Malaysia. In addition, the Ministry 
of Health’s Pharmacy Services Division has developed and 
implemented credentialing and privileging for pharmacists who 
have been working in specific areas of practice; and this move 
towards specialisation supports the development of specialist 
competencies.
PWDG 6: Leadership development 
Leadership development frameworks for healthcare 
and pharmacy
In Singapore, leadership development opportunities are available 
on the institutional and national levels. Institutions have in 
place leadership development programmes (such as self, team, 
organizational leadership programmes) offered to identified 
individuals for succession planning. On a national level, the 
Ministry of Health’s (MoH) Healthcare Leadership College (HLC) 
offers leadership programmes for identified candidates with 
potential to be groomed into future leaders for the profession. 
The HLC supports the building of strong leadership capacity and 
capabilities for Singapore’s national public healthcare system, in 
line with the MoH’s vision and strategic priorities. HLC developed 
the S.E.E.D Competency Framework (described in more detail in 
section 3.4); the Framework which serves as a basis for leadership 
programme development. The framework describes the core 
leadership competencies that are required of leaders at all levels 
(Self, Enabling, Execution, Direction). 
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Barriers to leadership development
Ghana reports challenges to implementation of this PWDG. 
Though there are guidelines and procedures governing 
professional leadership, they are not usually adhered to. The 
use of appraisal systems in guiding promotions and leadership 
development is also reportedly suboptimal.
Resources and initiatives for leadership development
Malaysia’s professional pharmacy association and other 
institutions provide workshops and trainings for leadership. 
Active collaborative projects between two student 
organisations, the Malaysia Pharmacy Students Association 
(MyPSA) and the Young Pharmacists Chapter of MPS, are 
contributing to developing leadership skills in pharmacy 
students and young pharmacists. In addition, a promotional 
scheme for pharmacists working in the public sector and 
academia provide opportunities and incentives to climb the 
leadership ladder. 
In the United States of America, the Academic Leadership 
Fellows Programme targets the academic workforce; it prepares 
30 faculty members annually to assume new or expanded 
leadership positions in the academy. Almost 400 pharmacy 
faculty members have completed this year-long programme. 
The programme has demonstrated success as measured by the 
number of fellows that have risen to top academic leadership 
positions in colleges and schools of pharmacy and the retention 
of fellows in academia.
Argentina has reported that the current Pharmaceutical 
Continuing Education Programme, as well as a number 
of academic activities, contribute towards the leadership 
development of pharmacists. Pharmacists in the United Arab 
Emirates have access to some specific training programmes and 
CPD opportunities that target the development of leadership 
skills. Additionally, the National Strategy for Innovation directly 
calls for taking concrete steps in leadership development. There 
are some training programmes in China offering pharmacists 
opportunities to develop their leadership skills; there are also 
leadership programmes jointly developed and offered between 
some universities.
Great Britain’s RPS developed the RPS Leadership Development 
Framework, which is based on the national Healthcare 
Leadership Model (See Part 3.4 for more information). The 
RPS Foundation and Advanced competency frameworks are 
aligned with the RPS Leadership Development Framework. 
This Framework provides uniform development of leadership 
behaviours for all pharmacists and pharmaceutical scientists, 
outlining leadership attributes to which all members of the 
profession should aspire.
Developing leadership as a competency
Australia has placed emphasis on leadership as part of their 
competency development frameworks. The ‘Leadership 
and management’ domain in the new national competency 
standards (released in May 2017) were significantly expanded 
from the 2010 edition and include two standards which are 
universally applicable to all pharmacists: (4.1) Show leadership 
of self and (4.2) Manage professional contribution. The 
standards within this domain encompass the development 
of leadership and management expertise throughout a 
pharmacist’s career. For this reason, some standards will apply 
to early career pharmacists while others will apply only after 
significant career progression has occurred and the pharmacist 
is engaged in activities of greater complexity that impose higher 
levels of responsibility and accountability. 
Japan is working towards developing an advanced-level 
competency framework for pharmacists. This framework 
includes competencies for leadership to support pharmacy 
practitioners in Japan to develop their leadership. A national 
policy document ‘Training for leaders to lead community-based 
integrated care systems in their community’ outlines guidance 
for leaders to establish the community-based integrated care 
systems. While this policy does not address the leadership 
skills directly, it does provide strategies on how leaders need to 
progress the development of the integrated care system.
Developing leadership in students
Costa Rica reported that, at various stages of their educational 
journey, students develop leadership competencies through 
activities targeted at instilling both clinical and executive 
leadership. Often, these activities form part of curricular outcomes.
Paraguay identifies pharmacists as healthcare professionals 
with the capacity to lead, innovate, and uphold ethical 
standards; pharmacists are therefore expected to integrate into 
multidisciplinary teams, and be committed to the health needs 
of society. With this ethos, pharmacists are instilled early on 
with leadership-relevant skills such as problem-solving during 
undergraduate education and training. 
South Africa has incorporated leadership-development 
components into the undergraduate degree. At the 
postgraduate level, pharmacists may choose to pursue Master’s 
in leadership or business administration.
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the rational use of medicines. A national award and a special 
committee are in place to encourage events and projects that 
engage pharmacists, doctors, patients and other professionals. 
In the private sector, many initiatives have promoted 
pharmacists training in clinical practice, therapeutics 
management, pharmacy’s management, and other areas.
Singapore has a number of service programmes and initiatives 
that demonstrate the extent of pharmaceutical workforce 
service delivery: (i) courses are soon to be offered on non-
medical prescribing for pharmacists; (ii) the existence of 
team-based chronic disease management clinics (services) as 
part of the ambulatory residency (PGY2); and the provision 
of Medication Management Service (MMS) by trained 
pharmacists.
Integration with early education and training and advanced 
practice
Throughout pharmacy training in Costa Rica, there are 
several courses that address public health and specifically 
pharmaceutical services related to the promotion of healthy 
lifestyles.
Ghana’s pharmacy schools are contributing to the involvement 
of more pharmacists in health promotion activities and 
practice research. Existing efforts need to be strengthened 
with better collaboration between training institutions and 
stakeholders (e.g. ministry/policy, practitioners, other health 
professions and society).
Recommendations outlined in the RPS Vision for the 
pharmaceutical workforce in Great Britain put patients at 
the centre, encouraging a needs-based, outcomes-focused 
approach to professional pharmacy education and training 
for student and pre-qualification years. It also acknowledges 
that pharmacists will be integral to supporting patients at all 
stages of a clinical care pathway involving medicines. These 
recommendations are aligned with the RPS Roadmap to 
Advanced Practice; there should be high quality of education 
and training required from entry onto an undergraduate 
programme through to post-registration development 
(i.e. Foundation Training to Advanced Practice), to enable 
pharmacists to be ‘the best they can be’ for their patients. 
Clinical Pharmacists in General Practice (GP) are directly 
providing services to support meeting patients demands and 
the UK government has committed to funding the recruitment, 
training and development of more clinical pharmacists.
Argentina referred to recommendations by the Pan American 
Health Organization and the World Health Organization 
(PAHO/WHO) for pharmaceutical education and training. 
A Pharmaceutical services course for Primary Health Care 
managers is also available. 
In Kenya, both the diploma and internship programmes are 
built around the care-needs of the patient population served 
by Moi Teaching and Referral Hospital. 
PWDG 7: Service provision and workforce 
education and training 
Identifying pharmaceutical workforce services 
and practice scopes
Australia has developed a vision statement, ‘Building upon 
pharmacists’ practice in Australia: A vision for the profession’. 
The purpose of this vision statement is to inform members 
of the profession, pharmacy organisations, consumers, 
governments, other health professions and stakeholders 
of the preferred future practice of pharmacists in Australia. 
The statement endorses pharmacists as leading healthcare 
professionals in medication management and related 
activities, describes the focus, nature and quality of their 
practice and provides guidance for the advancement of 
their practice through integrated development of a range 
of key enabling domains. The document lays out a set of 
ten functions which pharmacists undertake in order to give 
effect to the vision; and eight Enablers which are key areas 
or domains requiring integrated development to enable 
pharmacists to undertake the functions.
Japan’s on-going project of developing competency 
frameworks is intended to shape and support emerging 
new models of care according to health needs of Japan. The 
national Vision also provides the foundation of the needs-
based approach to workforce development towards improved 
national health. 
Adopting multiple strategies and programmes
Multiple strategies to support the implementation of this 
PWDG in Brazil include the organisation and government 
funding of: a national professional and multi-professional 
residency system with grants for pharmacists, involving 
the development of the workforce through work education, 
integrated with the organization of health services, and based 
on social needs and determinants; postgraduate courses 
aimed at transforming the professional practices of the 
pharmaceutical workforce in public healthcare, promoting 
education in the context of services, including the training of 
preceptors, educational facilitators and pharmacists; state 
Schools of Public Health promote training programmes and 
courses for pharmacists and other healthcare professionals by 
focusing on management, governance and clinical practices; 
and a public database of international and national scientific 
journals and evidence-based information in health is available 
for all registered pharmacists, allowing any pharmacist access 
to apply evidence-based practices. Some initiatives have 
sponsored and encouraged professional actions to promote 
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Uganda’s reported that an innovative method of training field 
pharmaceutical workforce in skills and behaviours needed 
to effectively provide supportive supervision at health units 
is underway. Such skills are not exclusively knowledge-based 
and therefore need to be modelled and practiced. The aim is to 
implement a training approach centred on videos to engage 
the workforce in practicing supportive supervised interactions 
and critique their own and their peers’ practices.
The United States of America provided an example of how 
education strategies can drive and shape workforce service 
delivery at the local and national level. The Interprofessional 
Education Collaborative (IPEC) allowed a multiprofessional 
partnership in Colorado to change local law, increasing 
opportunities for all students. This led to the creation of an 
interprofessional, student run, free clinic in Aurora, Colorado. 
As a result of IPEC and its influence on member institutions, 
pharmacy and other health professions students have 
provided needs-based interprofessional patient care across 
the country. For example, at the University of Colorado, 
all 160 pharmacy students in each class participate in IPE 
introductory pharmacy practice experiences (IPPEs) and 
half of these students choose to further engage in IPE-based 
advanced pharmacy practice experiences (APPEs). Activities 
include drug information consults, medication reconciliation, 
patient disease state education, medication device education, 
home visits focusing on transition of care, and participating in 
group diabetes appointments.
Regulated practice shaping workforce service provision
Healthcare facilities in the United Arab Emirates revolve 
around patient centred and integrated care. Service 
enhancement and workforce education and training are 
common policies of these healthcare facilities. It is also 
mandated by the healthcare regulators in the country that 
delivery of patient care be enhanced and this influences 
both the nature of pharmaceutical service delivery and the 
development of pharmaceutical workforce strategies.
This is one of only two referral hospitals in Kenya and has 
many unique patient care challenges for the learners to 
address. The patient-centred care models focus on both 
inpatient and outpatient settings. These opportunities include 
adult and paediatric medicine, community health, chronic 
diseases, reproductive health, surgery and anticoagulation. All 
care programmes are managed in conjunction with the Kenyan 
Ministry of Health.
Malaysia reported that most of the education providers engage 
the stakeholders (i.e. representatives from various practice sites; 
hospitals, community pharmacies, industries and regulatory). 
This is done to ensure that education is relevant to practice. 
Experiential learning in hospital, community pharmacy and 
pharmaceutical industry is a compulsory component in all 
pharmacy programmes. Exchanges between academics 
and practitioners occur through different platforms. Some 
universities engage practitioners as part-time lecturers and 
preceptors; a small number of academics continue to practice 
as locum pharmacists or at university-owned pharmacies. 
Namibia’s strategies towards fully implementing this goal 
are still under development. Currently, there are two running 
initiatives that complement each other. The University of 
Namibia School of Pharmacy has created a number of part-time 
positions that will bridge the gap between education/training 
and practice. The Ministry of Health and Social Services has 
also created positions that focus on education, training and 
research.
Zambia is committed to establishing a patient-centred 
and integrated health services foundation for workforce 
development; multisectoral engagement, in the form of 
collaboration through research, is one approach undertaken 
in Zambia. Similarly, China reported that developments have 
been made to establish patient-centred model of care for 
pharmacists to provide healthcare services.
Paraguay’s pharmacy students are prepared early on to deliver 
needed services. Students are taught to: promote the rational 
use of medicines in health professionals, patients and the 
community; provide advice on medicines for the prevention and 
treatment of diseases based on clinical studies and scientific 
evidence; integrate in multidisciplinary health teams in the 
administration, planning, programming, execution, evaluation 
of health campaigns and programmes; integrate in healthcare 
teams especially in Primary Healthcare; develop programmes of 
pharmaceutical care and provide pharmaco-therapeutic follow-
ups; design, direct and carry out research related to medicines 
and related in public, private and/or independent care centers; 
and manage institutions and human resources.
South Africa’s undergraduate curriculum accommodates 
experiential learning at various health facilities. This forms an 
important aspect of qualification development. The mandatory 
community service year also provides the opportunity to 
gain practical experience. At this stage, there is no universal 
programme for education providers to develop their capability 
and competency in this area.
23 | Research, Development and Evaluation Strategies
A clear feature of undergraduate education in Namibia, 
especially the pharmacy and medical training, is that students 
are taught together for about half of their curricula. There 
are attempts that the same is achieved for postgraduate 
programmes (e.g. MPharm and MMed Internal Medicine). 
Some universities in Malaysia have also initiated IPE elements 
in their curricula; these include National University of Malaysia 
(UKM), Monash University Malaysia, International Islamic 
University of Malaysia and University of Science Malaysia. 
Paraguay is training pharmacists such that they are able 
to work with other healthcare professionals and manage 
multiprofession human resource teams appropriately.
In Singapore, IPE was implemented at the National University 
of Singapore in 2010. The programme involves students 
from dentistry, medicine, nursing, pharmacy and social care 
work; and aims to prepare these students into collaborative 
practice-ready health workers. Students are taught IPE core 
curricula and carry out IPE-enriching activities to achieve 
6 competencies, namely (1) maximizing interprofessional 
teamwork, (2) effective communication with other healthcare 
providers, (3) optimising roles and responsibilities of members 
in an interprofessional team to achieve best outcome for 
patients, (4) building relationships with co-workers and 
patients based on shared values and ethics, (5) offering holistic 
care to patients, families, the community or special population 
groups (6) and achieving collaborative learning and reflections.
National policies, initiatives and practice programmes
Brazil reported two key strategies to be in place to support 
collaborative practice environments. The Multiprofessional 
Residency represents a strategy of collaborative work, 
integrating the diverse professions of health together. The 
Family Health Support Teams (NASF) were created in 2008 to 
support the consolidation of Primary Health Care in Brazil, 
expanding healthcare offerings in the service network, as 
well as the resolution, scope and target of actions. The NASF 
is configured by interprofessional teams that jointly carry out 
therapeutic projects and services. The NASF institution also 
collaborated to integrate pharmacists into primary healthcare 
workforces.
In Great Britain, the Foundation Programme and the Faculty 
both encourage teamwork and collaborations, which is clearly 
defined in their respective developmental frameworks.
Japan described multiple strategies and programmes 
that are aligned with the implementation of PWDG 8. The 
recommendations outlined in ‘Model core curriculum for 
pharmaceutical education’ policy document point out that 
pharmacy graduates are expected to gain basic team-working 
skills. On the other hand, the national guideline for training 
placements in undergraduate pharmaceutical education 
features collaborative working in a team-based healthcare as a 
requirement of each placement. 
PWDG 8: Working with others 
in the healthcare team  
Integrating interprofessional collaboration with education 
and training
Australia is conducting a review of the accreditation systems 
for registered health practitioners in Australia. The Australian 
Pharmacy Council is working as an active member of the Health 
Professions Accreditation Collaborative Forum to ensure 
that accreditation standards and processes facilitate the 
development of a workforce that engages in interprofessional 
collaborative practice. This includes the setting of 
interprofessional accreditation standards and cross-profession 
accreditation processes to ensure interprofessional education 
(IPE) elements are integrated into the workforce’s education 
and training.
The United Arab Emirates’ national Commission for Academic 
Accreditation mandates the inclusion of IPE and encourage 
collaborative practice in experiential learning. Medical schools 
and training facilities are shared by healthcare professionals. 
Pharmacy students are posted with medical students in 
clinical ward rounds in their internship. IPE committees are 
functioning in the educational institutions. 
Pharmacy students in Costa Rica receive several courses 
throughout their university education in which they 
must interact with students from other professions with 
the objective of developing projects that bring together 
the contribution of each professional area and various 
perspectives. 
Ghana also integrated IPE components into their 
education and training systems. This is exemplified by the 
institutionalisation of pharmacists in ward rounds with the 
wider healthcare team and the inclusion of nursing and 
laboratory orientations as mandatory courses in the current 
pharmacy programme. However, interprofessional training as 
a concept has not yet fully developed and Ghana believes that 
this is worth pursuing to encourage better collaboration and 
teamwork among health professionals.
Participants of both the diploma and internship programmes 
of Kenya work collaboratively with physicians, nursing staff 
and other health professionals and trainees throughout the 
entire programme. In addition, the diploma programme was 
created and approved by key stakeholders, which included 
pharmacists, physicians, nurses and hospital administrators.
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Facilitating interprofessional collaboration through practice
Collaborations between health professionals, especially 
among pharmacists, medical doctors, nurses and dietitians 
in Malaysia have been developed in most of the public 
hospitals and clinics. In most of the hospital wards, there will 
be a pharmacist who reviews medication use while working 
in multidisciplinary rounds. Pharmacists are also routinely 
involved in various interprofessional committees (e.g. drug and 
therapeutic committee, antibiotic stewardship, emergency 
and disaster management, etc.).
In Zambia, health professionals co-exist in practice and 
pharmacists often find themselves involved in integrated 
service delivery. Clearly, there is room for development in 
many nations. For example, China reported limited but existing 
communications between pharmacists and other healthcare 
professionals. 
Interprofessional collaboration in Portugal mostly takes 
place in hospital practice as the proximity between 
professionals has proved to be timely and advantageous 
in that setting. However, there is much variability as no 
regulations on hospital practice exist and they are arranged 
by the management of each hospital and depend on the 
availability of health professionals for these activities. 
Protocols of collaboration in specific areas are being piloted 
between general practitioners and community pharmacists 
to address non-complicated clinical conditions that will ease 
the burden on primary care services. Education and training 
on collaborative approaches to healthcare will be considered 
to support further activities within this scope. Student 
associations are lobbying for more collaborative learning 
elements. The Education & Practice Platform will also try to 
provide guidance on postgraduate training to involve several 
healthcare professionals as lecturers. 
Developing strategies for collaborative working for 
better health
South Africa identified the development of interprofessional 
collaboration as a critical element, particularly as the country 
prepares for introduction of universal health coverage and 
there is currently no national programme available.
The national competency framework that is being developed 
will clearly set out the competencies for collaborative 
working, which can then form the foundation for developing 
interprofessional education and training. Japan’s pharmacy 
leadership programme aimed at training leaders to lead 
community-based integrated care systems in their community 
clarifies a need of a collaborative working between all 
health and social care professionals and providers, which 
include a pharmacist as well. Finally, the Framework for 
training of pharmacists for the Health Support Pharmacy was 
developed in collaboration with other health and social care 
professionals to maximise the utility of pharmacists to support 
health of the public through community pharmacies; the 
Framework outlines that training should prepare pharmacists 
to be members of the community-based integrated, and 
multidisciplinary healthcare team. 
Multisectoral health professional collaboration
Australia’s National Translational Research Collaborative 
(NTRC) aims to drive high quality research that provides 
contemporary practice-based evidence to inform pharmacy 
practice and quality use of medicines. The NTRC will support 
junior practitioner development and enhance research 
capability through research mentoring/coaching/role models 
and inspire formal research aspirations & project involvement. 
A key focus of the NTRC is to ensure pharmacy research 
projects are up scale to work across multiple centres and 
across health-disciplines. In response, the Society of Hospital 
Pharmacists modified its research grants programme criteria 
to encourage funded research projects to be made up of 
interprofessional research groups.
In the United States of America, the Interprofessional 
Education Collaborative (IPEC) was established in 2009 by 
the American Association of Colleges of Pharmacy and peer 
organizations in Allopathic and Osteopathic Medicine, Nursing, 
Dentistry and Public Health. IPEC has contributed significantly 
to making IPE available to learners across the spectrum of 
health professions. Currently, a total of 20 health professions 
education associations are part of the IPEC Council. These 
associations have collectively produced core competencies for 
IPE, conducted more than 12 faculty development institutes 
serving over 300 universities and more than 1,500 faculty, 
and collected numerous educational resources to facilitate 
introduction and expansion of IPE at member institutions. 
The Pharmaceutical Society of Zimbabwe hosts an annual 
joint congress with the College of Primary Care Physicians. 
Also, the two national organisations have occasionally 
combined continuing professional education sessions.
Malaysia also reported that most of the continuing 
professional development (CPD) opportunities are co-
organized by the medical and pharmaceutical associations 
targeting the members of both professions. 
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practice using RPS standards and professional development 
frameworks in all care settings and for the ultimate benefit for 
patients. RPS Professional Development Programmes support 
CPD and meet regulatory requirements for continuing fitness 
to practise. The RPS Foundational and Advanced Frameworks 
also contain competencies for CPD and lifelong learning. 
Described earlier under PWDG 2, Japan has in place a quality 
assurance mechanism for lifelong learning programme; this 
national mechanism provides evaluation criteria to maintain 
the quality of pharmaceutical education in Japan. The joint 
project between leadership bodies in Japan and Great Britain 
will develop competency frameworks that will include CPD 
competencies. A national Vision statement describes the 
current and future roles of pharmacists in the team-based 
healthcare, from initial education to lifelong learning. 
All practicing pharmacists in Malaysia need to collect a 
minimum of 30 CPD points for the renewal of annual retention 
certificate. A list of criteria have been developed by the 
Malaysian pharmaceutical association and the Ministry of 
Health (MoH). Members of the association are able to record 
their CPD points online. In addition to the association, CPD 
providers include universities, pharmaceutical industries, chain 
pharmacies, hospitals, the MoH, and scientific journals.
In Namibia, all postgraduate programmes that serve as 
mechanisms for CPD/CE are needs-based programmes. CPD 
strategies in Paraguay are reportedly aligned to the strategies 
proposed in the National Health Policy. Similarly, China 
reported that pharmacy professional development activities 
are linked with some needs-based health policy initiatives and 
pharmaceutical career development pathways.
Portugal’s Pharmaceutical Society oversees a CPD credit 
system that awards pharmacists’ educational and professional 
activities with a numeric value. Credits attributed consider 
hours of a number of activities including: learning, practice, 
publication, tutoring/mentoring pre-registration students and 
patient monitoring, to name a few.
Mandatory CPD was implemented in 2006 in Singapore. The 
public sector offers a Ministry of Health Pharmacist Career 
Track for public patient care centred institutions.
There is no national CPD strategy in South Africa; but the 
introduction of the new competency standards in South Africa 
will drive the development of a CPD system, especially when 
the standards will be incorporated into the current on-line 
recording system. Similarly, having a future national CPD 
strategic plan is needed in Zambia. 
Pharmacists in the United Arab Emirates are required to 
complete 20 credit hours gained through accredited CPD 
events every year for the annual renewal of their registration.
PWDG 9: Continuing professional 
development strategies 
According to the revised Pharmacy Board of Australia CPD 
Registration Standard, pharmacists in Australia are required 
to plan their CPD on an annual basis in order to renew their 
annual registration. Pharmacists must: (1) reflect on their scope 
of practice, and any proposed changes to their practice, against 
the current National Competency Standards Framework for 
Pharmacists in Australia and identify relevant competencies; 
(2) identify professional development needs relevant to these 
identified competencies; and (3) identify suitable CPD activities 
which address these professional development needs. 
Costa Rica’s professional association has developed a 
functional Pharmaceutical Professional Recertification System 
since 2002. Currently, more than 750 members participate in it. 
The College promotes continuous pharmaceutical education 
through activities carried out both at its headquarters and 
in its subsidiaries. In addition, online pharmacy refresher 
courses are promoted in topics related to Primary Health Care, 
Pharmaceutical Care, Pharmacy Legislation and Ethics, among 
others, as well as in all aspects related to new legislation 
such as: Pharmacovigilance, Braille Medication Labeling, and 
Registration Sanitary of Medications. A biannual National 
Pharmaceutical Congress is intended, among many aims, to 
encourage continuous professional development. Additionally, 
the Faculty of Pharmacy of the University of Medical Sciences, 
through the Center for the Development of Pharmaceutical 
Initiatives (CEDIFAR), provides continuous education solutions 
to national and international professionals. In-person and 
on-line courses, synchronous and asynchronous, have been 
offered.
The CPD policy for pharmacists in Ghana provides a platform 
for self-directed learning. Practitioners can run their CPD 
programmes based on their practice/career needs and 
initiatives. The implementation of a mandatory minimum 
CPD credit points system sustains the career development 
pathways. In-line with new thinking of being socially 
responsive, targeted new programmes are to be developed to 
complement current programmes.
The professional regulator in Great Britain, the General 
Pharmaceutical Council, set out the standards for CPD 
requirements. All pharmacists and pharmacy technicians 
are required to comply or their registration may be put at 
risk. CPD entries must be structured according to the cycle 
of reflection, planning, action and evaluation. Strategies and 
vision statement put forward by the RPS support the need 
for pharmacists to demonstrate their skills, knowledge, and 
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According to laws in Namibia, affirmative action is in place 
to reduce inequalities at the level of employment. About 
70% of the student cohort in pharmacy education is female, 
showing no female gender discrimination within the 
admissions process; however, more work needs to be done 
on having better in-country regional representation in the 
student cohort.
PWDG 11: Workforce impact and effect on 
health improvement 
Conducting research to measure impact on health outcomes
Although there is no institutionalized national programme 
to evaluate the impact of the pharmaceutical workforce in 
Brazil, some research projects have evaluated the impact and 
results of pharmaceutical services positively impacting clinical 
outcomes in diabetes, for example.i 
Portugal reported a study conducted in response to a request 
by the Portuguese Pharmaceutical Society which estimates 
the value of the pharmacists’ interventions on health 
outcomesj. The study found that community pharmacists’ 
interventions provide a gain in quality of life of 8.3% and an 
economic value of 879.6 million Euros in Portugal.
South Africa has just completed the first phase of the 
introduction of universal health coverage. During this phase, 
a number of districts were chosen as pilot sites. The potential 
impact on health systems and health improvement were 
evaluated at some of the pilot sites. These evaluations are 
expected to inform future research to be conducted by the 
national, provincial and local authorities. Research that has 
already been conducted includes: assessment of the impact 
of pharmacy assistants support to primary healthcare clinics 
in terms of pharmaceutical management, budget control 
and loss control; development of an appropriate rural model 
to allow pharmacy assistants to up-skill to pharmacist 
technicians without disruption to services; and assessment of 
PWDG 10: Pharmaceutical workforce gender 
and diversity balances 
Diversity in the student body and academic workforce
Brazil’s “affirmative policies” aim to ensure opportunities 
for ethnic minorities. In public universities, there is a special 
admission process. In public institutions, there are job 
vacancies for ethnic minorities and people with disabilities. 
No policies are in place to ensure gender diversity in 
pharmaceutical workforce in either the public or private 
sectors, but the rate of woman is high in all sectors except 
in political positions where the rate of women is lower. 
In the United States of America, the Task Force on 
Diversifying Our Human Capital examined strategies 
that have worked in pharmacy education and other 
disciplines to insure a diverse student body and practitioner 
population that mirrors the diversity of the communities 
pharmacists serve. The Task Force report includes 
diversity statements for the academic community and 
for American Association of Colleges of Pharmacy and 4 
recommendations to advance the Association’s work in 
achieving diversity goals. 
All universities in Costa Rica are bound by a Resolution 
that targets strengthening the conditions of respect for 
those who work and study in the institution. The policy 
prevents, discourages, and punishes acts of discrimination 
on the basis of sexual orientation and/or gender identity. 
The University of Medical Sciences is developing a research 
project to address the issue of diversity and gender with 
students in their immediate environment and beyond. 
Ghana reported that gender parity has been attained with 
females comprising 49% of the student cohort. However, 
ensuring geographical equity in the admission process 
remains a challenge; students from less endowed schools 
are grossly under-represented. There is a policy to address 
this but the extent to which it is implemented has not 
been monitored. There are no gender restrictions on 
recruitments, promotions, career progression opportunities 
and leadership of the academic workforce. Women occupy 
a number of key executive positions across the country. 
Diversity in terms of race is not applicable but issues 
relating to representation of the under-privileged have to 
be addressed and monitored.
i  -  Determination of the effectiveness of Pharmaceutical Care in diabetic 
patients attended at a Popular Pharmacy in Brazil (Professor Mauro Silveira de 
Castro) http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4773513
D2#ProjetosPesquisa
 Evaluation of the economic impact of Pharmaceutical Care in patients 
with DM2 (Professor Leonardo Regis Pereira) http://buscatextual.cnpq.br/
buscatextual/visualizacv.do?id=K4769296A6#ProjetosPesquisa
j  -  Available at https://www.ispor.org/ScientificPresentationsDatabase/
Presentation/69183
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the role and impact of pharmacists and pharmacy assistants in 
integrated management of chronic conditions. 
Costa Rica promotes the dissemination of successful projects 
through poster presentations at national and international 
congresses. Collaborations between pharmacists and 
researchers in China are contiburitng towards evaluating 
impact of pharmacists on healthcare systems.
Access to essential medicines and emergency relief
In Ghana, there are over 15,000 pharmaceutical facilities 
distributed countrywide from which essential medicines are 
accessed. Some pharmacists were part of the emergency Ebola 
response team constituted in collaboration with the United 
Nations during the recent Ebola crisis. Current evidence on 
impact in Ghana is anecdotal; evidence on the impact of these 
activities on health is yet to be generated.
A widespread network of community and institutional 
pharmacies provide easy access to medicines and related 
products in the United Arab Emirates. Pharmacists provide 
the services to decrease medication errors, prevent and 
manage drug related problems and participate in public health 
projects. 
Policies and frameworks to facilitate impact-measurement
Japan’s future competency framework, which is currently 
under development, will allow for the measurement of the 
performances of pharmacy practitioners, which can in turn 
be used to provide evidence of the impact of workforce by 
analyzing with the other data in health systems. A national-
level framework set out to establish integrated care systems 
in the community in which pharmacists are primary health 
service providers; and these care systems are designed to 
meet the needs of the communities they serve based on need 
assessments. 
The Pharmaceutical Services Division of Malaysia’s Ministry 
of Health compiles evidence of impact of pharmaceutical 
services regularly. The results can be viewed by the public in 
its official websitek. Additionally, academics and practitioners 
conduct and publish studies on impact of pharmacists and 
pharmaceutical services. 
Similarly, Paraguay reported that the Ministry of Public Health 
and Social Welfare does keep records. Also, it is considered 
that workforce intelligence also provides a measure of impact; 
Paraguay’s Register of Professions lists more than 3500 
registered pharmacists. 
Zimbabwe’s Human Resources for Health Information System 
(ZHRIS) is another example of using workforce intelligence 
databases as a basis for measuring access to services and 
impact. The project is a national one and will incorporate the 
pharmaceutical workforce once it is fully fledged.
Establishing the National Pharmacy Strategy in Singapore 
provided an opportunity to critically review the impact of 
the services provided by pharmacists in the local health 
eco-system. This exercise gathered essential feedback and 
evidence for the value of the pharmaceutical workforce and 
how this value can be further enhanced to meet the needs 
of the local health system and the health service users. 
With the aging population and more prevalence of needs 
for maintaining good mental health, pharmacists are also 
beginning to play more active roles in these areas. Future 
development will include pharmacists becoming non-
medical prescribers, working in collaboration with doctors 
to optimise treatment for patients. In addition, pharmacists 
are also becoming more involved in regulatory affairs and 
pharmacovigilance; ensuring people in Singapore have access 
to quality health products.
Scaling up the workforce to maximise impact
A national workforce survey is currently underway in Namibia 
to measure the exact impact of education on the workforce; 
however, no work is being done to measure the impact of 
workforce on health systems and improvement. It is assumed 
by Namibia that having increased the workforce by about 15% 
in the last 3 years will have had a measureable impact.
PWDG 12: Workforce intelligence 
Workforce intelligence strategies under development
Australia’s Pharmacy Leaders Forum (APLF) advocates 
for government investment in modelling and pharmacist 
workforce planning. The APLF is an independent coalition of 
senior decision-makers from national pharmacy organisations 
who work together on issues of national importance to the 
pharmacy profession and the public. Pharmacy is the fourth 
largest registered healthcare profession in Australia, and 
forward planning to ensure the pharmaceutical workforce 
can meet the ever-changing needs of patients and the future 
health system, is crucial. The pharmacy profession currently 
has no ability to predict with any degree of accuracy, the 
balance between supply and demand for pharmacists and 
what the balance should or will be at any given time in the 
future. Existing ‘Australia’s Future Health Workforce’ (AFHW) 
reports contain detailed modelling on workforce supply, k  -  http://www.pharmacy.gov.my/v2/en/statistik
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Currently, a workforce survey 2017 is underway. 
The United Arab Emirates collects intelligence on pharmacy 
students and the academic workforce through the Centre For 
Higher Education Data and Statistics, an agency that collects 
and analyses statistics from all higher education institutions. 
The National Health and Family Planning Commission in 
China publishes annual reports of the workforce and their 
distribution across different practice settings. 
PWDG 13: Workforce policy formation 
Focus on the pharmacy support workforce
The ‘Redesign Project’ was commissioned by the Society of 
Hospital Pharmacists of Australia (SHPA) in 2016. Its aim was 
to review current roles of hospital pharmacy technicians/
assistants, identify variations in scope of practice, and 
barriers to change. The project included a literature review; 
a review of supporting frameworks; and additional primary 
research including a national survey, three focus groups, 
six structured interviews with key stakeholders, and four 
case studies of innovative practice. The study found that 
pharmacy technicians have a limited career structure and the 
lack of opportunities to advance practice stifle development. 
Training and education quality, consistency and availability, 
needs to be improved. SHPA is now working towards 
updating current standards and workforce definitions and 
developing an Australian pharmacy technician/assistant 
competency standards framework and exploring SHPA’s role in 
credentialing individuals for defined competency areas from 
entry level to advanced level.l
Priorities for workforce policy formation
Ghana employed strategies that are mainly centred around 
the following milestones: minimum entry requirement into 
pharmacy programmes; mandatory pre-registration training 
for all undergraduate students; professional examinations; 
and mandatory post-registration training and CPDs based 
on regular practitioner needs assessment and emerging 
health needs.
demand and training, for doctors, nurses and oral health, 
and projects numbers required of these workforces up to 
2030. There are no such AFHW reports for pharmacists. The 
APLF continues to work with government to implement 
a longitudinal study of the pharmacist workforce. This 
would enable development of an Australian pharmaceutical 
workforce strategy and ensure the nation maintains the right 
pharmacist workforce capacity and capability.
The Pharmaceutical Council in Ghana is in collaboration with 
the Ministry of Health (MoH) in leading a national strategy 
to collate, manage and share workforce data and planning 
activities. 
Currently a national workforce survey is being undertaken in 
Namibia; this will be complemented by separate surveys of 
graduates and students. The data will be shared with major 
stakeholders (Ministry of Health; Health Professions Councils; 
Pharmaceutical Society; National Planning Commission) to 
coordinate properly and plan for the future workforce.
Improving workforce intelligence on pharmaceutical scientists
Although evidence does exist on the National Health Service 
pharmaceutical workforce in Great Britain, comparable 
information on pharmaceutical scientists is lacking– a 
shortcoming that needs to be addressed. The RPS’s New 
Medicines, Better Medicines, Better Use of Medicines guide 
stipulates that research and information to support workforce 
planning is vital in making a case for resources.
National workforce intelligence strategies and programmes
Japan’s healthcare professional workforce observatory 
provides national workforce data and trends of workforce 
development. The collected data are used to consider the 
future workforce planning.
Malaysia’s national workforce intelligence strategy is 
coordinated by the Pharmaceutical Services Division of the 
Ministry of Health, particularly the Pharmacy Policy, Strategic 
Planning Division and Pharmacy Practice and Development 
Division and the Pharmacy Board of Malaysia. Workforce 
issues are also being looked after by the pharmaceutical 
association and the Council of the Deans.
The National Parliament of Portugal issued a bill giving 
the Central Administration of the Health System (ACCS) the 
responsibility of collecting data for the National Inventory of 
Health Professionals, including the public, private and social 
sectors. This individual register, still under construction, will 
allow the completion of the current exhaustive individual 
database on the public sector, adding individual and reliable 
data on the private and social sectors.
The Singapore Pharmacy Council conducts a workforce survey 
once every 10 years. The last survey was held in 2007/08. 
l  -  For more information about Redesign Project, see: https://www.shpa.org.
au/pharmacy-technician-assistant-training-0
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Policies that are currently being formed in Japan include the 
collaborative programme between the Japanese Pharmacists 
Association and the RPS of Great Britain. The research project 
will develop competency frameworks for pharmacists in Japan 
based on validated and utilized framework in Great Britain 
in collaboration with the RPS. A national vision statement for 
pharmacy describes the current and future roles of pharmacists 
in the team-based health are; the national vision was developed 
considering the needs in health systems in Japan.
The South Africa pharmacy council undertook research towards 
this PWDG. Their Human Resources for Pharmacy document 
outlines the recommendations for strategies that are needed to 
develop the required workforce. 
Multisectoral workforce development 
In Malaysia, the development of pharmaceutical workforce 
from initial education and training through advanced practice 
is being looked after by a number of stakeholders working with 
the national pharmaceutical association and these include 
the Pharmacy Practice and Development Division within the 
Ministry of Health, Pharmacy Board of Malaysia, Malaysian 
Qualification Agency, Council of the Deans, and other relevant 
associations.
In Paraguay, the pharmacy profession engages with employers 
to identify the workforce profile required by them. 
Workforce development in Namibia focuses on scaling up 
the pharmaceutical workforce through in-country education 
and training. The future strategies for the development of 
pharmaceutical cadres will focus on the up-skilling of pharmacy 
assistants to technicians and of pharmacists to Masters 
holders. The latter is intended to lead to the development of 
specialisations from Masters-level graduates.
A surveillance of the pharmacy landscape in Singapore has been 
conducted since 2014. Stakeholders from all pharmaceutical 
and healthcare sectors were invited to participate in feedback 
and strategic planning sessions. This approach is taken to 
ensure that future development of the profession and its 
workforce will be needs-based. The data from these activities 
were crystallised into a 14-items National Pharmacy Strategy 
which was approved by the Ministry of Health in 2016.
Focus on quality assurance in education
The United Arab Emirates workforce development is carried 
out through the accreditation of pharmacy education, 
continuous professional development, and through accrediting 
institutional healthcare facilities. This is a combined effort by 
different strategies by Ministry of Education and pharmacy 
regulatory agencies. An international partnership with the 
Accreditation Council for Pharmacy Education (ACPE), USA is 
intended to facilitate to accreditation/certification visits to 
pharmacy educational institutions in the UAE.
2.3.3 Priorities for forward planning 
The case study authors were asked to identify the PWDGs 
which are priority areas for development and/or evaluation in 
their nations over the next five years. The following Table 2.2 
summarises the results.
Most countries are prioritizing a significant number of the 
PWDGs, with many of the countries listing all of the PWDGs as 
priority areas for improvement. However, some of the PWDGs 
appear to be of lower priority in a high proportion of countries. 
Such as, PWDG 10 (pharmaceutical workforce gender and 
diversity balances) which is only prioritized in four countries. 
Interestingly, PWDG 10 has the lowest number of countries 
mapped against it; indicating that many countries are not 
meeting this goal but are also not prioritizing it for development 
or evaluation.
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Argentina
Australia
Brazil
Chile
China
Costa Rica
Ghana
Namibia
Paraguay
Portugal
Singapore
South Africa
Uganda
UAE
USA
Zambia
Zimbabwe
Great Britain
Japan
Kenya
Malaysia
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Table 2.2: National five-year priority PWDG areas for development 
                     and/or evaluation.
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Background
The development of a high-quality workforce is essential to 
the strengthening of health systems worldwide1. Investing 
in health workers by scaling up their education and training 
is linked to expanded access to health care services and 
improved health outcomes2. Recently, global strategies and 
initiatives by bodies such the WHO, the United Nations and the 
World Bank have provided unprecedented support for policy-
makers and stakeholders aiming to transform education 
and training internationally. Appropriately skilled health 
workers not only improve patient and population health, but 
a transformed workforce can also impact on employment and 
the economy. The purpose of up-scaling the knowledge, skills 
and abilities of the international pharmaceutical workforce is 
to help strengthen health systems worldwide. 
Making health systems stronger requires a continual process 
of change, which begins with on-going improvements 
in professional education and training. As a health care 
profession that provides evidence-based care related to 
medicines use, high-quality pharmacy education is often 
underpinned by the outcomes of robust research. Scientific 
studies on best practice in healthcare guide the advancement 
of current knowledge and techniques provided through 
education and training, which in turn promotes innovative 
practice. Research and development (R&D) is, therefore, a vital 
component of world-class pharmacy education and training. 
3.1 Evaluation and impact for global 
workforce development
Author: Darrin Baines, Professor of Health Economics, 
Bournemouth University, United Kingdom (dbaines@
bournemouth.ac.uk).
Driven by:
Summary
a. Continual research, development and evaluation 
is essential to the on-going success of the global 
pharmaceutical workforce and the health systems it 
serves.   
        
b. Evaluation of the value of health service outcomes is 
essential to measuring workforce Impact, one of the 
Pharmaceutical Workforce Development Goals (PWDG 
11). 
c. Existing frameworks for evaluation can be applied 
in pharmacy as tools to assess the impact of the 
pharmaceutical workforce.   
d. The ‘Logic model’ and the World’s Health Organization 
‘Monitoring and Evaluation Framework’ can be 
combined in a model for evaluating the effectiveness of 
pharmaceutical services in any practice  setting. 
e. Careful planning of evaluation studies is critical for 
the successful tracking of workforce impact on service 
delivery and improved patient and population outcomes.
PART 3
STRATEGIES FOR ADVANCING THE GLOBAL 
PHARMACEUTICAL WORKFORCE AGENDA
PWDG PWDG general description.
Countries/territories and member 
organisations should have:
Rationale, drivers, and potential indicators
11. Workforce 
impact 
and effect 
on health 
improvement
Evidence of the impact of the 
pharmaceutical workforce 
within health systems and health 
improvement. 
• Engagement with systems to measure the impact of the 
pharmaceutical workforce on health improvement and 
healthcare outcomes. Links with needs-based education, 
training and workforce planning.
• Gather continuous data points to monitor the performance 
of the pharmaceutical workforce.
• Ideally, this should be linked with strategies to enhance 
workforce intelligence.
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Resources/
Inputs
Activities
Planned work Intended results
Outputs Outcomes Impact
impact of innovations in pharmacy practice. Producing such 
evidence is vital because health systems require a constant 
flow of information that enables decision-makers to choose 
which programs to fund. This is especially important for the 
implementation of Pharmaceutical Workforce Development 
Goal 11: ‘Workforce impact and effect on health improvement’. 
The “logic model” is a tool developed by the W.K. Kellogg 
Foundation to facilitate effective program planning, 
implementation and evaluation3. According to the Foundation, 
their framework is a systematic way of presenting and sharing 
understanding about key relationships between program 
resources, activities and results. Figure 3.1 outlines the basic 
Kellogg model, with five main stages in project operation and 
delivery. The Foundation recommends that their conceptual 
diagram is accompanied by program narratives describing the 
sequence of activities that will bring about change and how 
these activities will create expected results. Using the diagram 
and associated narratives, the logic approach can be used to 
plan evaluations of new pharmacy interventions implemented 
in a health systems setting. Although there are different ways 
to assess change, the Kellogg’s framework allows competing 
methods to be sense-checked by stakeholders before formal 
evaluations begin. This ensures that the chosen approach 
to analysis properly captures the types of data required to 
fully assess the value of new programs. For this reason, logic 
modelling should be at the heart of pharmacy RDE.       
To promote health systems strengthening, R&D must create 
changes in professional knowledge, skills and abilities that 
improve health and well-being at both patient and population 
levels. For decision-makers, understanding what works (and 
what doesn’t) is vital to the continual process of generating 
beneficial change. On the ground, health systems require 
constant monitoring and observation that chart progress and 
quality over time. Assessments of the value of the outcomes 
produced by individual systems are also required. In sum, 
continual research, development and evaluation is essential to 
the on-going success of the global pharmaceutical workforce 
and the health systems it serves.
Logic models: applications in pharmacy
Whilst the concept of R&D is well-understood and regularly 
used in pharmaceutical research, the importance of evaluating 
the role of pharmacists in health systems strengthening 
is currently less recognised. The FIP roadmap for the 
pharmaceutical workforce, which is aligned to global health 
workforce strategies, has promoted a better understanding 
of the necessity of continual workforce development as a 
means of improving patient and population outcomes. Future 
work by FIP is ought to support the profession in generating 
reliable evidence about the effectiveness, efficiency and 
Figure 3.1: The basic logic model.
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Resources/
Inputs
• Clinical 
pharmacist
• Screening 
databases
• Switch of 
medications
• Better 
patient health
• Economic 
productivity gains
• Senior support 
nurse
• Inviting parents 
for review
• Deprescribing
• Improved 
well-being
• Improved 
population health
• Consultation 
room
• Patients 
diabetes check
• Reduction 
in risk
• Better informed 
patients
• Health system 
strengthening
• Medical 
consumables
• Face-to-face 
consultations
• Patient 
reassurance
• Greater patient 
satisfaction
• Administrator/
receptionist
• Referral or letter 
to GP
• Hospital or GP 
visit booked
Activities Outputs Outcomes Impact
Together, these two stages describe the planned program 
of work. Next, the logical model consists of three stages 
that describe intended outputs, outcomes and impacts. In 
relation to outputs, the diabetes clinics are planned to deliver: 
medication switches; de-prescribing; risk reductions; patient 
reassurance; hospital and GP visits. If these outputs are 
produced, the following outcomes will be secured: improved 
patient satisfaction; reduced risk; more informed patients; 
better health; fewer emergencies. As well as generating direct 
benefits for patients, the diabetes clinics will have an impact 
on the wider community in terms of: economic productivity 
gains, improved population health and strengthened health 
system. As this simple example illustrates, logic models may 
be used to specify the resources, activities, outputs, outcomes 
and impacts that should be captured in pharmacy practice 
evaluations performed in a health systems context.  The model 
can be applied across all sectors and practice settings.
Using an example from pharmacy practice, Figure 3.2 shows 
how a logic model may be constructed in the context of 
health systems strengthening. Using medicines review clinics 
for diabetes as an example, the visual representation of the 
logic model is designed to illustrate program strengths and 
weaknesses and to help stakeholders examine different 
project scenarios. Logic models should make apparent the 
assumptions that stakeholders hold about how and why their 
programs will solve problems, generate new possibilities and 
make the most of scarce resources. Reading from left to right, 
the first stage in the example is the identification of resources 
and program inputs. This stage lists the following inputs into 
the planned diabetes clinics: clinical pharmacist; support 
nurse; consultation room; consumables; administrator/
receptionist. If these resources are used appropriately, 
then the following activities may be performed: database 
screening; sending of invitations; health checks; consultations; 
referrals and General Practitioner (GP) letters.
Figure 3.2: Logic model for hypothetical drug review clinics for diabetes. 
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WHO framework for monitoring and evaluating 
health systems
The logic model is used worldwide to plan programs for 
health systems strengthening. The approach requires the 
identification and collection of appropriate data in each of 
the five stages. In 2009, the WHO presented a framework for 
monitoring and evaluating health systems strengthening 
at both country and global levels4. The Kellogg and WHO 
frameworks both picture the process of change in terms 
of key stages, with the latter describing the “results chain” 
in terms of inputs and processes, outputs, outcomes and 
impact. As a means of consolidating the two approaches, 
Figure 3.3 is a modification of the WHO monitoring and 
evaluation framework that better describes the ways in which 
pharmacy practice may be assessed in the context of health 
systems strengthening. Like the logic model and the WHO 
approach, the proposed model is built around key stages. First, 
resources in terms of capital, workforce and consumables 
are used to provide planned activities. Next, outputs are 
created through work processes embodied in: pharmacy 
practice infrastructure; technologies that enable pharmacy 
provision; medicines supply systems; pharmaceutical care; 
information systems. These processes can create a range of 
outputs, including improved access to medicines, database 
screening, medicines reviews, provision of patient services, 
public health activities, reductions in risks, patient education, 
reduced side-effects and fewer emergencies. In turn, the 
outputs produce outcomes that can be measured in terms 
of patient health status, changes in well-being and levels of 
patient knowledge. As well as these patient-specific benefits, 
pharmacy practice outputs can generate societal impact in 
terms of economic productivity, population health and health 
systems strengthening.
Collection, analysis and communication
Central to the WHO model is a focus on the importance of data 
collection, analysis and communication in health systems 
monitoring and evaluation. Data is collected from a range of 
sources, which often differ between the stages being sampled. 
These include: provider estimates, patient questionnaires, 
patient and population surveys, clinical reporting systems and 
official government statistics. As service provision and data 
collection are regulated in most countries, the model shows 
that pharmacy practice, monitoring and evaluation usually 
occurs within an institutional framework. An “institution” may 
be defined as the “law, regulations, policy, rules, conventions, 
ethics and norms governing behaviour”. In most countries, 
the institutions governing pharmacy practice, data collection 
and health systems are clearly defined in national law and 
professional codes of conduct. Next, Figure 3.3 shows that 
data analysis may take three main forms: evidence synthesis, 
statistical analysis and qualitative studies. Descriptions of 
these approaches are provided in the accompanying boxes. 
Finally, the diagram illustrates that collected information 
may be used for national and global monitoring and 
reporting. When pursuing the 13 Pharmaceutical Workforce 
Development Goals, country-specific and international 
communications will be vital in demonstrating pharmacy’s 
contribution to health systems strengthening.
Evaluation methods
Although Figure 3.3 displays the structure of data collection, 
analysis and communication in the proposed model, the 
framework does not specify which forms of evaluation should 
be employed. As Figure 3.4 shows, there are different ways to 
evaluate health system interventions, often related to specific 
disciplines of analysis. (The disciplines are shown in brackets 
in the following text). First, there are study types that include 
resource-use in their analysis. These include costing studies 
(financial), economic evaluations (economic), productivity 
measurement (economic) and workforce studies (labour). 
Combining workforce, productivity and output data are 
human factors studies (ergonomics). Next, impact case studies 
(funder) and benchmarking (management) are concerned 
with the consequences of producing planned outputs. Finally, 
outcomes research (public health) focuses on population 
health. Whilst these short descriptions do not convey the 
complexities of these different modes of evaluation, it can be 
concluded that: (i) there are alternative ways of evaluating 
pharmacy practice in a health systems context, (ii) no single 
approach covers the whole picture, and (iii) there many 
ways that the pharmacy profession can assess its success 
at delivering beneficial change. These conclusions suggest 
that the proposed framework outlined in Figure 2.3 may help 
evaluators decide the study types that best suit the aims of 
their work.    
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Figure 3.3: Proposed framework for monitoring and evaluating health   
                        systems strengthening.
Formal evaluations are performed using structured study designs, which differ depending upon data 
to be collected and objective of work
Combination of analytical techniques and modelling to join together multiple sources of evidence 
to support health systems decisions
Collection, analysis, interpretation, presentation and organisation of data to measure relationships, 
differences and uncertainty
Non-quantitative methods exploring underlying reasons, opinions and motivations 
that provide insights or help develop new hypotheses
FIP’s workforce development goals require data collection at both the country and the global level, which requires 
information to be collected and analysed as part of health systems monitoring and evaluation studies
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Workforce 
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Human 
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Production Outputs
Costing Economic evaluation Outcomes research
Inputs ImpactOutcomes
Figure 3.4: Study types that may be used to evaluate health 
                        systems strengthening.
Conclusions
The logic model is clearly established as a tool for facilitating 
effective program planning, implementation and evaluation. 
The WHO framework for monitoring and evaluation 
operationalises the logic model approach in a health systems 
context. The hybrid model presented here builds upon the 
strengths of the both frameworks by better describing the 
ways in which pharmacy practice may be evaluated in the 
context of health systems strengthening. This model can 
be used by evaluators of the ways in which the pharmacy 
workforce can help strengthen the delivery of health systems, 
particularly when the knowledge about the relationships 
between activities and results are required.  Given the 
importance of measuring the results produced by pharmacists 
pursuing the global workforce development goals, the careful 
planning of evaluation studies is vital.
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The global drivers
Meeting the pharmaceutical care needs of patients can only be 
achieved if a flexible and adaptable pharmaceutical workforce 
is deployed appropriately to apply its knowledge, skills, 
attitudes, behaviours and abilities to the maximum as part of 
the multi-disciplinary team.1 The World Health Organization 
(WHO) stated that there is ‘no health without a workforce’.3 
However, it is also true that there is no health workforce 
without workforce intelligence since effective deployment 
relies on the understanding of the state of the workforce 
in each nation: its quality, accessibility, acceptability and 
availability.1
The Global Vision for Education and Workforce4 acknowledged 
the worldwide variability in the education, training and 
utilisation of pharmacists, pharmaceutical scientists and 
pharmacy support staff. The Global Vision is underpinned by 
its 13 Pharmaceutical Workforce Development Goals (PWDGs) 
including one on workforce intelligence (PWDG 12) which says 
that without workforce intelligence there can be no strategic 
workforce intelligence.5 Workforce intelligence provides 
strategic workforce information to support workforce 
planning. It may also be used for assessing the performance 
of the workforce i.e. the impact on patient care. Workforce 
plans built on workforce data from local, regional and national 
perspectives may also ensure that the pharmaceutical 
workforce is effectively integrated to the health workforce to 
meet the health needs of patients and public.2 This requires 
3.2 From workforce intelligence to 
workforce development
Author: Christopher John, Global Workforce Observatory 
Lead, FIPEd; and Head of Workforce Development, Royal 
Pharmaceutical Society, United Kingdom (christopher.john@
rpharms.com).
Driven by:
Summary
a. The World Health Organization (WHO) stated that there 
is ‘no health without a workforce’.1 However, it is also 
true that there is no health workforce without workforce 
intelligence. 
b. Workforce intelligence is one of the International 
Pharmaceutical Federation’s (FIP) Pharmaceutical 
Workforce Development Goals (PWDG 12).
c. Workforce intelligence provides strategic workforce 
information to support workforce planning and 
expanding access to healthcare delivery.
d. It is important to illustrate trends in the pharmaceutical 
workforce to understand if the supply of pharmacists, 
pharmacy technicians and pharmacy support workers 
is keeping pace with population growth and disease 
burden.2 
e. The global pharmaceutical workforce will continue to 
be monitored and assessed in order to shape workforce 
development and capacity, thereby realising the 
Pharmaceutical Workforce Development Goals.3
PWDG PWDG general description.
Countries/territories and member 
organisations should have:
Rationale, drivers, and potential indicators
12. Workforce 
intelligence
A national strategy and 
corresponding actions to collate 
and share workforce data and 
workforce planning activities (skill 
mixes, advanced and specialist 
practice, capacity). Without 
workforce intelligence data there 
can be no strategic workforce 
development.
• FIP should aim to have a global workforce compendium of 
case studies developed by 2019.
• Develop monitoring systems to identify workforce trends 
to enable decision making on deployment and supply of 
pharmaceutical workforce noting that time-lags are often 
present in these activities. 
• Ideally, this should be linked with stewardship and 
leadership for professional leadership bodies.
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workforce intelligence systems and workforce planning 
models. The FIP workforce development goal of workforce 
intelligence therefore links closely to other goals such as 
PWDG 13: Workforce Policy Formation (i.e. strategies to 
implement needs-based workforce development) and PWDG 
11: Workforce Impact (evidence of the impact of the workforce 
on patient outcomes).3
The WHO, in its vision to accelerate progress towards 
universal health coverage, has also described an objective 
of strengthening data on human resources for health.6 This 
links to other objectives focused on policy development 
and investment in human resources for health aligned with 
population health needs. Milestones include nations having 
in place workforce registries and processes for sharing data4. 
Other WHO guidelines recommend governance and planning 
including national plans to produce and retain graduates in 
the health workforce informed by needs and intelligence in 
the labour market.7
Of course workforce intelligence is not an end in itself – 
there is little value in collating workforce data if the data is 
of no value i.e. does not influence decisions on policy and 
planning. In a similar way, only data that effectively assesses 
the impact of the workforce should be produced.5 Workforce 
intelligence systems must deliver consistent, relevant data at 
the right time, in the right place. Unfortunately, data is often 
difficult to obtain and quality varies. Agreement between 
key stakeholders is needed to describe important workforce 
information that needs to be collected.5
The trajectory must be workforce intelligence informing 
workforce development policies and plans which in turn 
mobilises national investment in the health workforce.
The Global Pharmacy Observatory: Workforce
Global pharmaceutical workforce data has been collated since 
2006.8 Indeed, analysis of data from 20099 and 201210 enabled 
trends to be monitored over the period 2006-2012.11 The 
pharmaceutical workforce are medicines experts who play a 
vital role in improving health outcomes through the effective 
and responsible use of medicines. It is important to illustrate 
trends in the pharmaceutical workforce to understand if the 
supply of pharmacists, pharmaceutical scientists, pharmacy 
technicians and pharmacy support workers is keeping pace 
with population growth and disease burden.12 Alignment of 
workforce intelligence with an understanding of these factors 
is vital as well as developments in technology and social 
values.2 
The future FIP Global Pharmacy Observatory will build on the 
original Global Pharmacy Workforce Observatory and provide 
an integrated global pharmacy-related information hub that 
can be used to inform advocacy work, policy development, 
decision-making, the advancement of pharmaceutical practice, 
sciences, education and of course workforce intelligence. 
This gateway to pharmaceutical workforce statistics will 
inform more effective workforce development and workforce 
planning to transform and scale up the workforce, in particular 
for those countries that face workforce shortages as they 
are able to benchmark themselves against other nations. For 
instance, the 2009 data highlighted the workforce shortage 
in Kenya that eventually supported the introduction of a 
residency training programme.10
The FIP 2017 survey of its member organisations included 
questions on the pharmaceutical workforce, the aim of which 
was to collate a core data set e.g. total number of practising 
pharmacists per nation. This, as in previous years, will provide 
a standardised measure: density of pharmacists (number of 
pharmacists per 10,000 of a nation’s population) for nations to 
benchmark against one another. If a country has a low density 
of pharmacists this does not on its own indicate a shortage. 
However, if a shortage is established and another core data 
including numbers of pharmacy graduates remains static 
over a period of time it is unlikely that this will be addressed 
without investment in educating more pharmacists and/or 
importing pharmacists via migration. Core data such as these 
examples can act as a trigger for research in order to further 
understand the profile of a country’s workforce and the 
challenges and opportunities that it faces.
Future work
The global pharmaceutical workforce will continue to 
be monitored and assessed in order to shape workforce 
development and capacity thereby realising the 
Pharmaceutical Workforce Development Goals.3 Trends 
over the period 2006-2017 will be analysed following the 
2017 FIP survey of its member organisations. Further work is 
also needed to develop professional, economic and disease 
indicators to describe the impact of the pharmaceutical 
workforce mainly (though not exclusively) following 
investment of resources by national economies.
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d. There remain a number of barriers to achieving Academic 
Capacity on a global scale. 
e. Integrated research, development and evaluation 
strategies are required to fill the current gaps and drive 
global implementation of the academic capacity goal.
3.3 Building academic capacity and the 
academic workforce
Author: Claire Anderson, Academic and Institutional Capacity 
Lead, FIPEd; and Professor of Social Pharmacy, School of 
Pharmacy, University of Nottingham (claire.anderson@
nottingham.ac.uk).
Driven by:
Summary
a. Academic Capacity is one of the Pharmaceutical 
Workforce Development Goals (PWDG 1).
b. Having a competent and capable workforce depends on 
the capacity of the academic workforce to teach   
and train. 
c. Careful planning of the academic workforce is a critical 
component of developing academic capacity. 
PWDG PWDG general description.
Countries/territories and member 
organisations should have:
Rationale, drivers, and potential indicators
1. Academic 
capacity
Engagement with pharmaceutical 
higher education development 
policies and ready access to leaders 
in pharmaceutical science and 
clinical practice in order to support 
supply-side workforce development 
agendas.
• Increase the capacity to provide a competent pharmaceutical 
workforce by developing initial education and training 
programmes that are fit for purpose, according to national 
health resource needs (clinical practice, pharmaceutical 
science areas and stakeholders across all cadres). 
• Develop new and innovative ways to attract young 
pharmacists into all areas of pharmaceutical practice and 
science (e.g. encourage young pharmacists to consider careers 
in clinical academia, as preceptors/trainers, in industrial 
pharmacy, regulatory sciences, nuclear and veterinary 
pharmacy, among others).
• Capacity building should include the ability to meet minimum 
national standards of facilities, educators and student 
support in order to ensure access to quality education for all 
students.
• Enhance interprofessional education and collaboration 
with key stakeholders, including governments, national and 
international pharmacy/pharmaceutical organisations and 
patient advocacy groups to achieve sustainable solutions for 
capacity development. 
• The clinical academic educator workforce needs more 
attention to training, career development and capacity 
building, which must, importantly, include research capacity 
enhancement.
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Background
Building academic capacity refers to any effort being made 
to improve the abilities, skills, and expertise of educators 
and of those being educated. It can include human capacity 
building as well as institutional capacity building for example, 
buildings, equipment and infrastructure. The capacity to 
provide pharmaceutical services, cost-effective healthcare, 
research, innovations in technology and pharmaceutical 
industry in each country is dependent upon having a 
competent, adaptable and capable workforce, and a similarly 
integrated academic workforce to train and support sufficient 
numbers of new registrant pharmacists and other support 
staff at both entry-to-practice and advanced levels. 
The Pharmaceutical Workforce Development Goal Academic 
Capacity (PWDG 1) calls for all countries and FIP member 
organisations to engage with higher education development 
policies and have ready access to leaders in pharmaceutical 
science and clinical practice to support supply-side workforce 
development agendas. 
The 2013 FIPEd Global Education Report1 suggests that 
pharmacy education, in both capacity and infrastructure, 
varies considerably between countries, territories and WHO 
regions, and generally correlates with country level economic 
development indicators. Those countries and territories with 
lower economic indicators tend to have the least academic 
capacity and produce fewer pharmacists. 
A global independent Commission on the Education of 
Health Professionals for the 21st Century reviewed the global 
status of postsecondary health professional education and 
concluded that:2
“All health professionals in all countries should be 
educated to mobilise knowledge and to engage in critical 
reasoning and ethical conduct so that they are competent 
to participate in patient and population-centred health 
systems as members of locally responsive and globally 
connected teams”. 
The Commission adopted a global outlook, focussing on 
the health needs of populations, recognising the increasing 
demand for integrated health-professionals' education and 
leadership, and took a systems approach to educational 
reform, considering health professionals' education itself as 
a system that overlaps with the health system it attempts 
to serve. Despite this, educational systems and specifically 
universities are not currently held accountable for the 
professionals they develop.
Planning strategies for the academic workforce
Pharmacy programmes increasingly focus on employability 
and producing ‘work-ready’ graduates who are initially 
recruited based on having a vocation in the profession. The 
move towards massification reduces the time that individual 
students can expect to spend in one-to-one contact with 
teaching staff. A focus on research as a key income stream in 
countries, such as the UK, appears to be leading to greater use 
of teaching-only contracts. In the UK, an increased number of 
pharmacy degree programmes has led to rapid promotion of 
academic staff and to shortages as people who were research 
and teaching active academics have been forced to focus on 
developing new programmes.
Academic workforce planning needs to be part of the whole 
system of pharmaceutical workforce planning. For example, 
if a country plans to increase graduate output but has a 
shortage of academics and preceptors to teach, then this 
quantitative scale up will not be sustainable. Workforce 
planning in pharmacy education establishments is crucial 
given the need to recruit and develop staff over an extended 
timescale, often in competition with other organisations from 
the same small pool of academics. Senior management needs 
to be engaged in this too and succession planning is crucial. 
There is a need to look at the numbers and types of staff, levels 
and expertise, the changing skills required, role profiles, work 
allocation, performance and productivity. 
Global strategies for academic capacity
The WHO ‘National Health Workforce Accounts: A Handbook’ 
calls on all countries to establish accreditation mechanisms 
for health training institutions by 2020.3 It also calls on 
countries to improve health professionals training completion 
rates, and to reduce their dependency on foreign-trained 
health workers by half, thereby implementing the WHO Global 
Code of Practice on the International Recruitment of Health 
Personnel.4 Extrapolating this for pharmacy, the major policy 
questions that need answering regarding academic capacity 
are on production of pharmacists by educational institutions, 
gender distribution and how the current gaps can be partially 
addressed by increasing investments in education and 
production. 
The National Health Workforce Accounts has two modules 
relating to academic capacity. Module 2 ‘Health workforce in 
education’ indicators aim to map and track health workers 
in education and training, including the status of pre-entry 
applicants, new entrants and graduates (Figure 3.5). The 
provided dimensions can be used to plan and monitor 
student selection and enrolment, and assess existing policies. 
In addition to facilitating workforce-specific analysis, the 
indicators provide information on gender as well as public/
private institution distribution. Understanding distribution on 
a subnational level can also allow for tracking and managing 
geographical imbalances.
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Module 4 ‘Education finances’ aims to support the 
development of an effective financing system that can 
strengthen intersectoral collaboration between education, 
lifelong learning and health systems. Figure 3.6 lists the cost 
of education and training indicators, which include the ratio 
of health education expenditure to total public education 
expenditure, and to gross domestic product (GDP). Other 
indicators include the cost per graduate as well as the cost of 
educators per graduate. Analysing this information can serve 
several purposes such as: estimating attrition-linked loss, 
supporting retention mechanisms and policies, and better 
understanding on how targeted investments promote gender 
equality and health equity; this can in turn generate evidence 
on utilising future investments in health workforce education 
according to needs.
Health workforce in education
Pre-entry and entry into education 
and training
• Applicants to education and training 
places ratio
Entry into education and training
• Entrants to education and training 
places ratio
• Entrants to education and training 
programmes by cadre
• Sex distribution of entrants, by cadre, 
by institutional ownership
• Ratio of foreign-born entrants
• Entrants to educators ratio
Graduates from education and 
training programmes
• Sex distribution of graduates by 
cadre, by institutional ownership
• Graduation rate by cadre
• Education output by cadre, by 
institutional ownership
Education finances
Cost of education and training
• Ratio of expenditure on health 
workforce education to total public 
expenditure
• Ratio of expenditure on health 
workforce education to GDP
• Ratio of public expenditure on health 
workforce education and training to 
total public expenditure on education
• Cost per graduate
• Cost of educators per graduate
• Cost per graduate in medical 
specialist education programmes
• Ratio of expenditure on in-service 
training to total public expenditure 
on education and training
• Average tuition fee by education and 
training programme 
Figure 3.5: WHO National Health Workforce Accounts: Corresponding   
                       dimensions for Module 2 Health workforce in education.
Figure 3.6: WHO National Health Workforce Accounts: Corresponding   
                       dimensions for Module 4 Education finances.
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Current gaps, drivers and opportunities
There is very little existing data on academic capacity 
in pharmacy globally and it is imperative that member 
organisations, regulatory bodies, health departments, 
educational institutions and other stakeholders start to collect 
and review this data alongside other workforce data. 
Qualitative data from the 2013 FIPEd Global Education 
Report1 indicates that there is a global shortage of pharmacist 
academics and of practice based supervisors/preceptors. 
This has happened for several reasons. One response to 
workforce shortages was a planned expansion of the number 
of pharmacy graduates, which occurred or was recommended 
in countries like Australia, Canada, Ireland, Malaysia, the United 
Kingdom, and the United States. In developing countries, 
there is an increasing trend towards adopting the Doctor 
of Pharmacy (PharmD) degree, which is characterised by 
having a considerable number of clinical preceptors. In parts 
of the Middle East, Africa, and countries like Bangladesh, 
India, Pakistan and Thailand are changing their entry-level 
qualification to a PharmD. Yet, many of these regions and 
nations do not have a sufficiently trained and available clinical 
pharmacists who are competent to act as preceptors.5
As the pharmacy curriculum evolved to become more clinical, 
some countries have employed more clinical academics who 
may be working in practice but spending some time teaching 
and some time researching. However, in some countries 
including many developing countries, all academics have been 
required to have PhDs and be active in both research and 
teaching. There is a dilemma though, exemplified in the current 
UK situation, as the curriculum has become more clinical and 
more integrated, many leading universities have appointed 
academics to teaching-only contracts and fewer people are 
coming into academia via more traditional routes; leading 
to there being too few people to become full professors and 
associate professors in clinical pharmacy, social pharmacy and 
pharmacy practice. Academic promotion has become largely 
based on teaching with less of a focus on research output. 
The understanding of pharmacy education and the significant 
influencing factors, are essential for planning human resources 
for health and for achieving universal access to medicines and 
medicines expertise. Collaboration with key partners, including 
governments and national and international pharmacy 
organizations, is crucial to achieving sustainable solutions to 
the challenges surrounding pharmacy education. 
There is a need to define, measure, build, and monitor the 
academic capacity required to produce the workforce 
necessary for safe and effective medicines discovery, 
manufacture, distribution, and use. The Nanjing Global 
Conference on Pharmacy and Pharmaceutical Sciences 
Education ran a number of workshops to address the drivers 
and challenges of achieving the PWDGs on a global scale. At the 
workshop on PWDG 1 Academic Capacity, a number of priorities 
were identified: (1) defining “fit for purpose” during a time of 
great change in healthcare and education, (2) recruiting and 
training classroom and practice-based instructors for new and 
non-traditional pharmacy roles, (3) academic collaborations 
with practice, industry, and interprofessional stakeholders, 
(4) practice-based definitions of pharmacists, pharmacy 
technicians, and other support cadres, and (5) the need to 
include students in discussions of academic capacity. 
Workshop participants agreed that while local needs may vary, 
academic capacity was an important global issue. Diagnostic 
models and benchmarking tools are needed to help countries 
estimate the number of and specific competencies for 
pharmacy-related academics. Additionally, pharmacy leaders 
must develop skills in advocacy in order to demonstrate to 
educational, healthcare, and financial policy makers the value 
of investing in the pharmacy-related academic workforce. 
This investment is critical for the future of safe and effective 
medicines development, access, and use. 
Barriers identified included the wide range of degree offerings 
(diploma, BPharm, MPharm, PharmD) globally and potential 
misunderstandings about these, a lack of shared academic 
terminology, a lack of distance-based education models which 
could be critical in achieving capacity, mistrust associated with 
historical brain drain from lower-middle income countries, 
local legal constraints in education, and a disconnect between 
academic advancement expectations (teaching, research, 
service) and outcomes.
Approaches to researching, developing and 
evaluating academic capacity
While previous work regarding counting, and describing 
pharmacy-related academics has been initiated (see FIP Global 
Pharmacy Workforce reports listed Annex 3), the output of this 
work has not been complete nor has it been used widely to 
drive policy. Diagnostic models and benchmarking tools are 
needed to enable these numbers to motivate global action as 
well as to be useful in needs-based educational models.
A whole systems approach over a long period of time is needed 
for countries to bring about the changes required. Evaluation 
needs to be coproduced and developed with all stakeholders. 
A mixed methods approach needs to be employed, using a 
range of established evaluative techniques designed to assess 
process, outcomes and impacts. It is also necessary to focus 
on key quantitative variables around supply of graduates, 
employability and analysis of competencies and measures 
of stakeholder satisfaction. It will be important to explore 
effectiveness of partnerships, both qualitatively and through 
use of tools like social network analysis. Curriculum change 
can be analysed through standard curriculum evaluation 
methodologies, for example with the FIP benchmarks as a key 
reference point for the pharmacy students. 
Standard lesson observation approaches can be utilised, 
followed by staff interviews that discuss pedagogical and 
curricular matters and probe issues of lecturer identity and 
satisfaction. Wider institutional capacity development can be 
44Research, Development and Evaluation Strategies | 
explored through interviews with university managers. Wider 
impact could be explored through longitudinal, multi-methods 
case studies. It takes time to sustainably embed learning and 
develop new institutional policies, practices and partnerships 
that will deliver innovation and transformed professional 
education; and outcomes can only be measurable after many 
years. Meaningful indicators based on international norms and 
existing data capture practices can be used. There is a need to 
also draw on realist evaluation methods and political economy 
analysis, considering where processes have worked well, and 
where not and why change did and did not happen. 
Many challenges remain and succession planning is important 
to build the academics of the future. What will the 21st century 
academic look like? Will they be the same as previously and do 
they have to do it all? Are researching-alone or teaching-alone 
work modes enough? New pathways for clinical academics 
should also be developed; for example, the UK’s University of 
Nottingham has developed a ‘research practitioner’ role where 
young practitioners have been employed to do a PhD, teach 
and maintain their practice. The National Institute of Health 
Research in England has opened up their clinical fellowships, 
lectureships, professorships to pharmacists wishing to pursue 
a clinical academic career. Other countries also need to look at 
promotion routes/tenure tracks for clinical academics that are 
resource-tailored and needs-based. 
PWDG 1 on academic capacity provides an opportunity to 
develop the passive and active surveillance systems required 
to produce the pharmacy-related workforce necessary for safe 
and effective medicines discovery, manufacturing, distribution, 
and responsible use worldwide. Research, evaluation, 
development strategies are required to fill the current gaps and 
allow for the sustainable building of the academic capacity and 
the academic workforce.
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Why is leadership development important?
Leadership development is defined as expanding the collective 
capacity of organisational members to engage effectively 
in leadership roles and processes.1 Leader development and 
leadership development are often confused to mean the same 
thing, when in fact they are two different concepts. Leader 
development involves the development of leadership skills 
and attributes of individuals, whereas leadership development 
involves a broader vision involving the organisation as a whole. 
A likely explanation for the inter-changeable use of the 
terms could be due to the fact that most leadership studies 
examined leadership as an individual phenomenon with a 
focus on behaviours and skills of leaders.2 However, leadership 
is a complex phenomenon, which involves the interactions 
between the leader and the social and organisational 
environments.3,4 Through this lens, leaders are expected to have 
the responsibility of building organisations, setting 
the vision for their organisation, and expanding their capacity 
to learn. 
Leadership development encompasses the development of 
organisations by using a broader and collective framework 
in which leadership is developed in practice and should 
involve everyone in the organisation.5 There is good evidence 
supporting the notion that leadership development is 
imperative in order for organisations to flourish in today’s highly 
competitive business environment; to achieve this, leadership 
needs to develop at all levels within the organisation.6-8
3.4 Leadership development: preparing 
the pharmaceutical workforce 
Author: Nadia Bukhari, Senior Teaching Fellow, Pre 
Registration Coordinator and UCL School of Pharmacy Alumni 
Coordinator, UCL School of Pharmacy (n.bukhari@ucl.ac.uk).
Driven by:
Summary
a. Investing in leadership development of the health 
workforce has been shown to enhance health system 
organisation and improve patient outcomes. 
b. Pharmaceutical Workforce Development Goal 6 
“Leadership development” calls on countries and 
nations to create leadership development strategies and 
programmes for their pharmaceutical workforce.
c. The UK’s national Healthcare Leadership Model 
and the Leadership Development Framework for 
pharmacy provide examples of tools and resources for 
implementing PWDG 6.
d. The efficient implementation of PWDG 6 relies on the 
integration of leadership development with other 
aspects of workforce development such as academic 
capacity (PWDG 1) and quality assurance (PWDG 2).
e. Overall, leadership development in pharmacy is under-
researched and little is known about the global status 
of pharmacy leadership strategies and needs which 
calls for concerted action led by FIPEd to drive evidence-
generation in this area. 
PWDG PWDG general description.
Countries/territories and member 
organisations should have:
Rationale, drivers, and potential indicators
6. Leadership 
development
Strategies and programmes in 
place that develop professional 
leadership skills (including clinical 
and executive leadership) for all 
stages of career development, 
including pharmaceutical sciences 
and initial education 
and training.
• Creation of programmes/strategies for the development of 
leadership skills (including tools and mentoring systems), to 
support pharmacists and pharmaceutical scientists through 
their careers.
• Advocacy for leadership development in healthcare teams, 
linked to collaborative working activities (for example, 
promotion of team-based approaches to healthcare service 
delivery). 
• Ideally, this should be linked with competency and 
foundation and early year career development activities.
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Both leadership development and leader development are 
equally important and necessary to increase the leadership 
effectiveness of an organisation.2 Leader and leadership 
development should be integrated to align to the organisational 
strategy and goals, which if achieved, will have the greatest 
possible impact for the organisational performance.9 
Leadership development and the health workforce
Preparing the healthcare workforce encompasses health 
system organisations; therefore the focus should be on 
leadership development, which encompasses leader 
development. Leadership development in healthcare has been 
identified as an important developmental skill globally. 
In the United Kingdom, there has been an increasing emphasis 
on the significance of leadership development in the National 
Health Service (NHS), the national health system which 
provides publicly funded health services to all UK citizens. An 
evaluation of a clinical leadership programme was conducted 
amongst nurses (n= 2000) and found that the programme 
improved the leadership capabilities of ward sisters and senior 
nurses and in turn contributed to improvements in patient 
care.10
In the United States, data from three qualitative studies of 
leadership development in healthcare were analysed and 
the results found that leadership development programmes 
provide four opportunities to improve quality and efficiency 
in healthcare:11
1. Increases the calibre of the workforce; 
2. Enhances the efficiency in the organisation’s education 
and development activities;
3. Reduces turnover and related expenses; 
4. And focuses organisational attention on strategic 
priorities.
It is important to understand the development of leadership 
attributes of practitioners, alongside the essential 
infrastructure and support mechanisms need for all levels of 
practice of the pharmaceutical workforce. The development 
of appropriate education and training strategies and plans 
targeted at these attributes will then result in a capable and 
competent workforce.
This aligns with the WHO statement, “no health without a 
health workforce”, which acknowledges that the delivery of 
better health requires a workforce that constantly develops 
and grows to better deliver increasingly complex and evolving 
health services.
Leadership, leadership development and impact of leadership 
is under-researched within the pharmacy domain. However, 
parallels can be drawn from the findings from healthcare and 
translated into pharmacy. 
Leadership development: global progress
Examples of global progress towards developing leadership 
in pharmacy have been reported through the country case 
studies collected for this report (section 2.3.2). Strategies 
that target leadership development in health and pharmacy 
come in different forms. Both Australia and Japan emphasise 
leadership as a competency in their foundational and 
advanced competency development frameworks for 
pharmacy. In an effort to instil leadership early on, countries 
like Costa Rica, Paraguay and South Africa reported 
incorporating leadership-developing components in the 
entry-level education of pharmacists. Other countries reported 
using an array of resources and initiatives for leadership 
development, including continuing professional development 
opportunities and training programmes. Leadership 
development frameworks have been reported in Great Britain 
and Singapore, and an overview of these frameworks is 
provided below. 
The UK government commissioned a public inquiry into the 
failings in care at the Mid-Staffordshire NHS Foundation in 
2010; the results, reported in the ‘Francis Report’, highlight 
the implications of leadership at every level on the quality of 
healthcare service delivery.12 Leadership therefore became a 
focus for healthcare provision in the UK with the launch of 
the Healthcare Leadership Model for all health workers, and 
the Leadership Development Framework (LDF) developed 
by the Royal Pharmaceutical Society (RPS) in Great Britain 
(RPS) for the pharmaceutical workforce, as well as associated 
programmes of development aligned to these frameworks.
The Healthcare Leadership Model (HLM), developed by the NHS 
Leadership Academy, is available nationally to all healthcare 
professionals.13 The behaviours incorporated within the 
framework empower healthcare professionals to make a real 
difference to patient care and outcomes. The HLM depicts 
nine leadership dimensions, which have been evident to be 
important in improving leadership (see Figure 3.7). However, it 
must be appreciated that competence and ability can vary in 
each domain; therefore, individuals can assess their strengths 
using a four-level scale (Essential, Proficient, Strong, and 
Exemplary).
The RPS developed the LDF, which is based on the HLM.14 It 
provides all pharmacists and pharmaceutical scientists with 
a consistent, uniform approach to developing leadership 
behaviours to improve quality and efficiency in healthcare. The 
framework is inclusive and engaging, promoting leadership for 
everyone within an organisation.
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Leading with care
Sharing the vision
Evaluating information Connecting our service
Developing capability
Holding to accountInspiring shared purposeEngaging the team
Influencing for results
Figure 3.7: The Healthcare Leadership Model: Nine leadership dimensions  
                       (Reproduced with permission: Healthcare Leadership Model 
                       and associated graphics ©NHS Leadership Academy. All rights  
                       reserved.)
There is good evidence to suggest that 360 feedback is a 
positive process for leadership development. Individuals 
whose performance was rated low by their staff were rated 
higher again several months later, suggesting that these 
behaviours were modified by the direction given by staff.15 
Research also found that an improvement was noted in 
managers who attended a leadership training programme 
after receiving a 360 degree feedback in the dimensions that 
the participants had selected to work on.16 
The RPS has developed a roadmap to support the professional 
development of pharmacists in all stages of their careers.17
Pharmacists and pharmaceutical scientists are encouraged 
to complete a self-assessment questionnaire, developed by 
the Leadership Academy, which generates a detailed report 
on their strengths and weaknesses within the domains. 
The report can be used to complete the RPS Leadership 
Development Action Plan which can be used for appraisals and 
inform next steps for leadership development. 
A 360-degree feedback is available for the HLM and all 
healthcare professionals are further encouraged to participate 
with the feedback model. The 360- degree feedback is a 
professional feedback tool, which allows peer-review of an 
individual’s performance. Individuals receive confidential, 
anonymous feedback from colleagues at all levels. This 
typically includes the employee's manager, peers, and people 
that they manage. 
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Figure 3.8: The RPS Professional Development Framework18 
                        (reproduced with permission).
The RPS Roadmap is designed to identify a practitioner’s stage 
of development based on their experience in the workplace, 
competence and the ability to manage complexity and 
then identifying and accessing the support and assessment 
required to be recognised at that stage. 
The RPS describes three principal career stages for 
pharmacists illustrated in Figure 3.8. Within each stage, 
leadership development is essential. The modern concept of 
leadership is not a hierarchical one. There is therefore a need 
to cultivate leadership early on and it should be instilled as 
early as the undergraduate years. 
Singapore’s Ministry of Health established a Healthcare 
Leadership College (HLC).19 In line with the national health 
vision and strategies, the HLC aims to support developing 
leadership capacity for Singapore’s national public healthcare 
system. HLC develops and delivers high quality learning 
opportunities and programmes aimed for healthcare leaders 
working in the public health system. The programmes address 
leadership development, organisational development, 
and public service values. In doing so, HLC articulates the 
national vision for leadership into actions, drives leadership 
development and builds an institutional leadership culture, 
and injects thought leadership into the design and innovation 
of health system models. 
HLC developed the S.E.E.D Competency Framework which 
serves as a basis for leadership programme development. The 
framework describes the core leadership competencies that 
are required of leaders at all levels (Self, Enabling, Execution, 
Direction). 
Pre-Foundation
Mpharm Pre-registration Foundation stage 1
Continuing Fitness to Practise (CFtP)
Foundation stage 11 Advanced stage 1
1000 days1000 days2000 days
Advanced 
stage 11
1000+ days
Mastery
› 10 years
Foundation Faculty
Mpharm
Award Registration
Certificate 
of 
completion
MFRSI MFRP11 FFRPS
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Self 
A1
A2
A3
A4
B1
C1
D1
B2
C2
D2
B3
C3
D3
B4
C4
D4
Enabling
Execution
Direction
Demonstrating integrity 
and the personal qualities 
of a leader
Knowing oneself
Taking responsibility
Serving a greater purpose
Leading by example
Understanding and navigating 
complexity
Understanding context 
and influencing policies
Communicating and engaging
Managing resources, energising 
people, forging networks
Inspiring a shared vision
Empowering and 
developing others
Strengthening systems 
and processes
Making tough decisions in 
dynamic and complex situations
Building effective teams
Driving continuous 
improvement
Building a culture 
to enable change
Aligning personal values with 
organisational values and vision
Working with and 
through others
Managing 
and delivering
the strategy
Setting the direction 
and the vision
The S.E.E.D Framework describes 16 leadership attributes 
(listed in Table 3.1) of a healthcare leader's relationship across 
four dimensions:
1. Self – Demonstrating integrity and the personal qualities 
of a leader; 
2. Enabling – Working with and through others;
3. Execution – Managing and delivering the strategy;
4. and Direction – Setting the direction and the vision.
Each of the four dimensions is accompanied with a set 
of descriptors that serve to illustrate how the competencies 
progress as the healthcare leader progresses. These 
descriptors, listed in Table 3.1, are cumulative across the levels.  
Table 3.1: S.E.E.D Competency Framework dimensions and descriptors.
In addition the S.E.E.D Competency Framework which 
guides the work of the HLC, the College also offers an array 
of programmes such as Milestone Programmes 
(e.g. Healthcare Policy and Governance Programme), 
Development Programmes (e.g. Introduction to Systems 
Thinking) and Lectures (e.g. Distinguished Speakers Series).
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Leadership development for the global 
pharmaceutical workforce
As the global pharmacy leadership body, FIP prioritises the 
leadership development of the world’s pharmaceutical 
workforce. Pharmaceutical Workforce Development Goal 
(PWDG) 6 is “Leadership development” and the goal calls on 
all nations and countries to create national programmes 
and strategies for the development of leadership skills (both 
clinical and executive) throughout the career pathways of 
pharmacists and pharmaceutical scientists. In the UK, there is 
a range of national programmes and courses to support and 
cultivate leadership development in healthcare and pharmacy 
as exemplified by the HLM and LDF, respectively.
PWDG 6 states that these strategies should ideally also 
be linked with foundational education and training and 
early career development. For example, the RPS Leadership 
Development Framework’s four-level scale allows for 
assessment of leadership at all practice levels. 
Across all PWDGs –from academic capacity to workforce policy 
formation, leadership development cannot be implemented 
without integrated planning throughout all PWDG clusters; in 
turn, this integration allows for the efficient implementation 
of the other individual goals. 
For example, PWDG 6 Leadership development can be 
driven through integration with continuing professional 
development/education (CPD/CE) strategies. CPD/CE plays 
a key role in developing leadership and as such, there needs 
to be integration between leadership goals and educational 
goals which is an important link for professional development. 
One simple way to achieve this would be to incorporate 
leadership with CPD requirements; resources for professional 
development can incorporate materials for leadership 
training and development. For example, the UK Centre for 
Pharmacy Postgraduate Education, which offers professional 
development opportunities for the pharmaceutical workforce, 
established a ‘Leadership school’ – a four-day programme 
over a 12-week period for developing leadership skills in the 
workplace and improving patient outcomes.
 
Another example of integrated planning is to incorporate 
leadership requirements in quality assurance strategies 
(PWDG 2); by doing so, pharmacy educational providers and 
pharmacy schools would be accountable for demonstrating 
leadership development components in their curricula 
and programmes. The General Pharmaceutical Council 
(GPhC), which regulates the pharmacy profession and 
specifies standards for pharmaceutical education in the 
UK, requires evidence of leadership development in the 
undergraduate pharmacy curricula from pharmacy schools. 
The GPhC “Standards for the initial education and training of 
pharmacists” stipulates that graduates – as clinical decision 
makers – must be able to demonstrate leadership skills as 
well as ‘lead change’. In addition, the academic faculty must 
also include pharmacists who are leaders in their profession. 
Integrating leadership development skills as part of education 
and training standards can be a means not only to nurturing 
leadership in the pharmaceutical workforce early on, but also 
developing academic capacity (PWDG 1).
Moving forward with leadership for pharmacy
Because of the complex nature of leadership the need for 
high integration between leadership and other aspects of 
workforce development, FIP member organisations (MOs) can 
benefit from support tools and resources to guide them in 
the development of leadership in their workforces. From the 
UK model, we have learned how leadership development can 
be integrated throughout all stages of workforce from early 
education all the way to advanced practice. The UK case study 
also illustrates the implementation of national leadership 
frameworks in the pharmaceutical sector of the health 
workforce. We can also see practical examples of integration 
between leadership development and CPD and quality 
assurance. All of these approaches and models can serve as 
guidance for other nations to create their own needs-based 
leadership development programmes and strategies. 
Developing evidence-based tools and resources, expert 
guidance, global leadership frameworks, local/institutional 
case studies, and research studies or projects (e.g. PhD 
and MPhil) can all guide nations in building leadership 
development strategies. Exploratory work could help 
understand the leadership needs of the global pharmaceutical 
workforce. The status of leadership in pharmacy is a largely 
abstract concept, and data is required to establish workforce 
intelligence. The data obtained from this can be used to 
identify themes to create a foundation for a global leadership 
framework. The evidence can also be used to create tools, 
resources and guidance for the workforce to overcome 
implementation barriers such as those reported by Ghana 
(section 2.3.2). 
Leadership training and development can maximize 
productivity and shape a positive culture. To achieve this, we 
must understand leadership in more detail and therefore more 
research around leadership in pharmacy is needed. Studies 
that further explore the established attributes for leadership 
and understand and explain how these connect with health 
service delivery, clinical leadership and the current health 
service needs would be recommended.
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health workers. Recognising the importance of technology use 
in health workers education, WHA’s Resolution (59.23) also called 
for “using innovative approaches to teaching in industrialized 
and developing countries, with state-of-the-art teaching 
materials and continuing education through the innovative use 
of information and communications technology.”7
The World Health Organization (WHO) produced its first 
guidelines on health workforce education in 2013.8 These 
evidence-based guidelines, presented in a report titled 
“Transforming and Scaling Up Health Professionals’ Education 
and Training”, emphasise the importance of scaling-up the 
health workforce’s educational and training systems such that 
they will adequately meet population needs. The guidelines 
present 11 Recommendations to transform and scale up health 
professionals’ education and training. Recommendation 5 is 
dedicated to ‘Simulation methods’ and asserts that, 
“Health professionals’ education and training institutions 
should use simulation methods (high fidelity methods in 
settings with appropriate resources and lower fidelity methods 
in resource limited settings) of contextually appropriate fidelity 
levels in the education of health professionals.”
WHO rates the quality of the evidence supporting this 
Recommendation as moderate, and the strength of the 
recommendation as strong. One of the Guideline’s key policy 
issues also focuses on the development of qualified educators 
and trainers as a crucial factor in health professionals 
education. Recruited faculty members must, in addition to 
possessing adequate clinical and scientific competencies, be 
prepared to function pedagogically and this includes being 
able to use new information technology. 
Technology and pharmaceutical education
Electronic health records (EHR) are a prime example of the 
intersection of information technology with healthcare, 
but they are only a single component in the broader health 
information technology (HIT) area. Recent US data surveys 
found that 84% of nonfederal, acute care hospitals9 and 
51% of office-based physicians had adopted a basic EHR.10 
Pharmacists therefore clearly need HIT skills; and Fox et al.11 
argue that informatics education should be incorporated in 
pharmacy curricula for all students.
Introduced in the US in the early 1990s, electronic prescribing 
systems automate the prescribing, supply and administration 
of medicines in hospitals. These systems can reduce 
medication errors and impact on patient safety.12 On the 
other hand, a poorly implemented system could increase error 
rates.12 There are also electronic discharge systems, barcode 
identification of medicines, robot dispensing systems, and 
telecare consultations and services.12 The number of HITs is 
growing rapidly, strengthening the argument of Fox et al.11
Author: 
Ian Larson, e-platforms and IT-based Learning Lead, FIPEd; 
and Director of Learning and Teaching, Faculty of Pharmacy 
and Pharmaceutical Sciences, Monash University (ian.larson@
monash.edu).
4.1 Introduction
Technology in pharmacy education
In the past twenty years, there has been a rapid expansion 
of the use of technology in education. The development of 
learning/course management systems such as Blackboard® 
coincided with a shift from overhead projectors to digital 
presentations like PowerPoint®. Education and technology 
are now inseparably intertwined.
Research has shown that universities, both public and private, 
acknowledge that technological innovation has had and will 
continue to have major influences on teaching methodologies. 
Institutional commitment to technology is also becoming 
a core differentiator in attracting students and corporate 
partners.1 A recent survey of 89 US institutions revealed 
that they all used course management system, 99% used 
presentation software, and about 90% of those surveyed are 
also using technology to assess student learning.2 From a staff 
perspective, technology can save time,3 offer self-paced and 
self-directed content,3,4 provide instantaneous feedback5 and 
deliver a constant message6 to many students. Students enjoy 
these same advantages of technology. For example, ‘lecture 
capture’ – an umbrella term that describes any technology 
through which educators can record what happens in their 
lectures and make it digitally available – allows students to 
make decisions on the time and place of their learning.
Technology is shaping the development of education by 
enabling multi-modal teaching, and transforming curricular 
structures and learning outcomes. As education is becoming 
more learner-centred, technology can support this process 
by providing students with platforms for individually-paced 
learning. Expanding access to educational and reference 
resources benefits both students and teachers. In terms of 
research, technology-driven academic collaboration is also 
contributing to rich research output. 
This section will explore the current trends in technology-
driven pharmaceutical education; discuss implications of 
this for workforce education and training strategies, and 
moving forward with capitalizing on technology to prepare 
a competent and capable workforce that will improve health 
and population outcomes. 
Technology and health workforce education
In 2006, the World Health Assembly (WHA) called on all Member 
States to contribute to a rapid scaling up of the production of 
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4.3 What are the opportunities offered 
by technology-driven education?
Improving patient care
Smith and Benedict classify educational technology into 
three categories: computer aided instruction, human patient 
simulation and virtual patients.14 In their review, they found 
that each technology has advantages over traditional 
education, but that these technologies also have their 
drawbacks. Benefits ranged from an improved learning 
experience, repetition and feedback opportunities, clinical 
variation and customizable individual learning.14 Possible 
drawbacks were cost, the need for technical support and 
infrastructure needs (staff time and space).14
Smith and Benedict conducted a review of the literature 
on the effectiveness of educational technologies to teach 
patient care skills to pharmacy students15. Educational 
technology was employed with more than 2700 students at 
12 colleges and schools of pharmacy in courses including 
pharmacotherapeutics, skills and patient care laboratories, 
drug diversion, and advanced pharmacy practice experience 
(APPE) orientation. Computer-aided instruction, human-patient 
simulation and virtual patients all offered advantages over 
traditional teaching methods. These advantages were mainly 
the result of improved learning experience fidelity, repetition 
opportunities, faculty feedback, clinical variation, and 
individualized learning.
Educational technology as a quality indicator
Technology is permitted in some accreditation standards. 
For example in the US Accreditation Council for Pharmacy 
Education standard 12.7, 60 hours (of the total 300 hours) of 
simulation may be used to mimic actual or realistic pharmacist 
delivered patient care situations.16 There are a number of 
technology based simulations including MyDispense17 (a free 
web-based community pharmacy simulation programme 
developed by Monash University, Australia) that could be used 
in this context. Ferrone et al. measured student perceptions 
of MyDispense in three US schools of pharmacy.18 Most 
students (76%) agreed or strongly agreed that it learning to 
use MyDispense is straightforward, and 75% reported that 
MyDispense cases are more realistic than paper cases; 84% 
of students also found that it offered a safe environment 
to make errors. 
Students view educational technology methods to have 
a positive impact on their learning. In their study, Stolte 
et al. surveyed 179 1st, 2nd, and 3rd year pharmacy students 
of whom 89% were comfortable or very comfortable with 
technology.19 The most frequently used technologies for 
educational purposes were in-class electronic presentations, 
course materials posted on the school web site, and e-mail. 
Students responded that course materials had the most 
4.2 Global educational technology 
methods/trends in pharmaceutical 
education
This section will serve as a review of the literature exploring 
the latest trends/methods in technology. There is a wide array 
of ways technology is used in pharmacy education. They vary 
greatly in terms of how capable and complex they are.13
Human-patient simulation
Human patient simulators are high fidelity mannequins with 
integrated computers to produce clinical functionality such as 
respiratory movement and ECG monitor readings. Physiologic 
outputs change in response to student interventions. 
Healthcare students can use these simulators to learn airway, 
breathing, cardiac and circulation management. As well 
as clinical skills, human patient simulators can be used to 
develop communication and teamwork skills. Although cost 
is a significant factor, human patient simulators have been 
shown to be effective and enjoyable learning tools.14 
Virtual patients 
 
Virtual patients have been used across a variety of healthcare 
disciplines to train students. Through simulating a lifelike 
clinical scenario, these virtual patients place the learner in 
a safe environment in which they can safely make clinical 
decisions. The students can apply their learning in a practical 
situation and feedback can be immediate.14 Virtual patient 
technology has been found to have two benefits: 1) it is 
effective for student learning; and 2) students enjoy using the 
technology.15
Computer-aided instruction
Computer-aided instruction (CAI) is a wide collection of 
technologies used in education ranging from lecture capture 
systems, learning managements systems, online instructional 
delivery and audience response systems. Given such a range of 
tools, and methods through which they can be implemented, 
one can find studies that support their use and studies that 
don’t.14 While CAI is widely used,2 careful planning should go 
into its deployment to ensure it has an impact on student 
learning.14
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beneficial impact on their learning. Approximately 50% 
of students indicated that a large amount of technology 
should be used (e.g. all course content is online, computer 
simulations, streaming video or audio to accompany 
live lectures) in the classroom. The students felt that the 
online course materials (posted on the school Web site, 
in-class electronic presentations, and e-mail) were the 
most beneficial educational technology at the school while 
video-teleconferencing and online testing were the most 
detrimental educational technologies.
4.4 What are the challenges 
of technology-driven education?
For all its advantages, technology can be a time-consuming, 
expensive, and disruptive innovation. 
A challenge of the introduction of new technologies such as 
a virtual patient case is the amount of resources and time 
required.14 Approximately 40 hours of time were dedicated to 
the design and development of an active learning virtual patient 
activity. This included case design, video lecture composition 
and recording, and virtual patient construction.
Barriers to implementing technology include student 
hesitation,20,21,22 the need for technical support/oversight,23,24,25 
cost, 24 ,26,27 and resource utilization (eg, space, faculty time).21,26 
A major disadvantage of high fidelity technologies such 
as human patient simulations is cost. The initial costs of 
implementing this type of learning include a simulator 
($US16,000 to $US90,000), a functional space for the equipment, 
and simulation specialist support to begin programming.28 
Technology is not always beneficial for learning. In the study 
of Stolte et al., the authors found that the technology most 
frequently cited as “most detrimental to your learning” was 
video-teleconferencing.19 While these results are likely due 
to various factors including technical difficulties, even when 
lecture transmission quality is satisfactory, students prefer 
in-person class activities to video-teleconferencing.
Faculty members’ adjustment to new technology and teaching 
methods may be a challenge to implementation. Adjustments 
to organizational practices such as promotion and tenure may 
encourage faculty members to embrace technology.29
4.5 Conclusions
Using technology in a focused, strategic manner in 
pharmaceutical education can lift engagement, enjoyment and 
improved student knowledge and skill. However, technology 
is not a magic bullet. If used without due consideration in the 
wrong context, it can be detrimental to these things. Educators 
must decide upon the appropriate technology for their 
educational context, resources and student cohort. When used 
successfully, technology can be a game-changing tool that can 
improve both the student and educator learning experiences, 
as well as positively impact patient health outcomes.
4.6 Free support tools and resources 
for educators
PharmAcademy
SABER, a site under FIP patronage for sharing and building 
education resources, was widely acknowledged to be a useful 
tool but was receiving only a modest number of visitors 
and resource uploads/downloads. Measures to increase 
traffic included adding a journal hosting system for the 
Pharmacy Education journal, adding news story and blogging 
functionalities and adding tools to facilitate the development 
and maintenance of communities of practice. PharmAcademy 
(www.pharmacademy.org) was created and will become the 
‘go-to’ place for pharmacy educators worldwide to connect, 
and share knowledge and resources. PharmAcademy is a 
community site designed to connect pharmacy educators 
globally. It delivers significant enhancements to the SABER 
service from which it is born, as mentioned above.
In fact, SABER is now just one of three principle components 
that make up PharmAcademy – the other two components 
being the updated portal for Pharmacy Education journal 
and a community networking component designed to 
keep educators informed and in touch with the pharmacy 
education world.
The new portal for Pharmacy Education significantly 
streamlines the review and publication process, and the 
informal community publishing and peer networking space 
invite the worldwide community of pharmacy educators to 
connect dynamically online.
Pharmacy Education journal
The journal (http://pharmacyeducation.fip.org) provides a 
forum for communication between academic teachers and 
practitioners in professional education, with an emphasis 
on new and established teaching and learning methods, 
new curriculum and syllabus directions, guidance on 
structuring courses and assessing achievement, as well as the 
dissemination of new ideas. The journal also recognises the 
importance of policy issues and current trends in the context 
of education and professional development. The journal 
publishes reports of research and innovation in all aspects of 
professional pharmacy education and training, case studies, 
country studies, innovations in laboratory and professional 
educational practice, reviews and reports on information 
technology in education and reviews of current literature. 
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The New York Times called 2012: The Year of the MOOC.32 In 
that year, MIT created not for profit MITx. When Harvard 
joined MITx, the name was changed to edX. UC Berkeley joined 
later that year. In December 2016 Harvard University and MIT 
surveyed their first four years of courses on edX.33 They looked 
at 290 courses with over 2.4 million unique participants. The 
media age of participants was 29, 33% of participants were 
female and 73% of participants held a bachelor’s degree.
Because of massive enrollments, MOOCs require instructional 
design that facilitates large-scale feedback and interaction. 
The two basic approaches are:
• Peer-review and group collaboration
• Automated feedback through objective, online 
assessments, e.g. quizzes and exams. 
MOOCs following the first approach are called connectivist 
MOOCs (cMOOCs), while those following the second approach 
are called broadcast MOOCs.
Even though enrolments in MOOCs can be in the thousands, 
only a small number of participants actually complete 
their course. Research indicates that the current average 
completion rate is around 15%.34
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The journal has a clear international perspective, and has a 
longstanding policy of facilitating publication, in particular for 
younger Faculty, those authors whose first language may not 
be English, and manuscripts from all regions seeking low cost 
engagement with the wider global community.
MyDispense
MyDispense (https://info.mydispense.monash.edu) is an 
online community pharmacy simulation that allows students 
to develop and practise their dispensing skills. Through 
highly interactive dispensing exercises, MyDispense allows 
students to develop skills and confidence in safe, best-
practice dispensing of pharmaceutical products. The web 
application supports a total dispensing experience, from 
initial communication with the patient and prescriber to 
professional advice when handing medicines to patients. The 
application features a dispensing system with many features 
of commercial dispensing programmes to give students 
an authentic experience in modern dispensing practice. At 
the end of each exercise, students receive rich, contextual 
feedback on their dispensing performance. Students are 
able to explore patient-based scenarios that they're likely 
to encounter in real life. Tutors can build new exercises by 
combining elements from a database of over 420 patients, 40 
prescribers and 2400 pharmacy products to create limitless 
scenario variations. Students must make professional 
decisions to successfully complete the carefully graduated 
exercises. The MyDispense environment is paperless for 
students. It utilises virtual representations of patients, 
barcodes, labels and products. Built using advanced web 
programming, it's designed to run on the broadest possible 
range of computers. Being web based, it's accessible from 
anywhere – on campus or from home – and doesn't require 
downloaded plugins or additional software. There are 
currently 43 different institutions using MyDispense.
Massive open online courses (MOOCs)
A massive open online course is accessed through the web 
with no limitations on attendance. Emerging from the 
open educational resources movement in 2008, the first 
MOOC “Connectivism and Connective Knowledge” had over 
2200 students who paid nothing.30 As other MOOCs were 
developed, other online learning resources were born. Khan 
Academy, Peer-to-Peer University (P2PU), Udemy, and ALISON — 
are similar to MOOCs and allow students to work at their 
own pace.
In 2011 Stanford University launched three MOOCs. The first 
was “Introduction Into AI”, led by Sebastian Thrun and Peter 
Norvig. Over 160,000 students enrolled. Two more MOOCs were 
led by Andrew Ng and Jennifer Widom. Following the publicity 
and high enrollment numbers of these courses, Thrun started a 
company he named Udacity and Daphne Koller and Andrew Ng 
launched Coursera. In January 2016, Coursera had 1580 courses 
and Udacity more than 120 courses.31
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A series of individual country-level case studies have been 
evaluated for this report; although not meant to be a 
statistically-driven sample, these country cases are indicative 
of the workforce planning and development priorities that are 
emerging across national leadership bodies. We believe that 
as a first step towards a situational description of the global 
workforce, these case studies show patterns and gaps on 
which a global strategy, reflected in local needs, should 
focus efforts.
It is clear that the full scope and range of the PWDGs is 
being addressed across nations. It is also clear that for 
some PWDGs there is a wider ‘gap’ in relation to others. For 
example, leadership development (PWDG 6) and workforce 
gender and diversity balances (PWDG 10) have less traction 
than competency development (PWDG 5) or CPD strategy 
development (PWDG 9).
It has also become clear, supported by some previous FIPEd 
reports5 that terminology describing workforce and education 
has become confusing; for example, the local meaning of 
“Foundation training” or “Specialist practice” has variance 
between countries and regions. Building a database of 
terminology can identify points of equivalence within the 
workforce lexicon.
Understanding the current global trends in research, 
development and evaluation and identifying knowledge gaps, 
drivers and opportunities for future work is clearly important. 
The case study findings reported in Part 2 of this report are 
intended to support national leadership bodies and member 
organisations in the effective implementation of a needs-
based pharmaceutical workforce development roadmap.
5.3 Evaluation and impact for global 
workforce development 
The logic model - described in section 3.2 as a tool for 
facilitating effective programme planning, implementation 
and evaluation – uses a hybrid approach to describe ways in 
which pharmacy practice may be evaluated in the context 
of health systems strengthening. Given the importance of 
measuring the results produced by pharmacists pursuing the 
global workforce development goals, an understanding of 
how to plan workforce impact evaluation studies is vital; yet 
this remains and underexplored area in research. The model 
can therefore stimulate researchers and experts to begin 
discussions on impact measurement.
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5.1 Implications for the 
pharmaceutical workforce 
Investing in the health workforce contributes towards 
universal health coverage (UHC), Sustainable Development 
Goals (SDGs) and strengthening health systems. The launch 
of the UN High-Level Commission on Health Employment 
and Economic Growth is testament to the value in 
investing in global health workers; and the UN Commission 
recommendations for transforming the health workforce 
are intended to drive progress towards the global health 
development agenda. 
As medicines experts, the pharmaceutical workforce 
plays a key role in improving health outcomes through 
optimizing the responsible use of medicines. Investing in 
the development of an adaptable, flexible, competent and 
well-distributed pharmaceutical workforce is an imperative. 
It is also imperative that we have both a clear vision and 
a set of actionable goals and plans for transforming the 
workforce.1 The Global Vision for Education and Workforce,2 
the Pharmaceutical Workforce Development Goals (PWDGs),3 
and the Nanjing Statements4 provide a global roadmap for 
pharmaceutical workforce development.  
Research, development and evaluation mechanisms are 
integral to achieving progress on our Global Vision and the 
PWDGs; global engagement to make research, development 
and evaluation strategies an important consideration for 
implementing the pharmaceutical workforce development 
agenda is critical. The aim of this current report is to start a 
dialogue and foundation for thinking about the scope and 
range of a research, development and evaluation agenda 
for the global and national workforces of pharmacists, 
pharmaceutical scientists and pharmacy support workers.
5.2 Developing a baseline for transforming 
the global pharmaceutical workforce 
One of the overarching purposes of this report is to provide 
a starting point for describing our current ‘baseline’ in the 
context of workforce and educational development. In the 
context of a Global Vision, we should be identifying our 
current position in order to plan for structured development.
PART 5
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5.7 Research and development in 
technology-driven education
Workforce development is clearly an educational issue – as 
outlined in the FIP Nanjing report.1 The educational research 
and evaluation agenda in pharmacy needs to be developed; 
and the research, development and evaluation associated 
with technology-driven education needs to be especially 
strengthened. Using technology in a focused, strategic manner 
in pharmaceutical education can enhance education and 
workforce development. Technology can also improve both 
the student and educator learning experiences, as well as 
positively impact patient health outcomes when used in the 
pharmaceutical and the health sciences education. Evaluating 
the impact of technology-driven education needs to be 
conducted to identify impactful ways to use technology in 
pharmaceutical education.
5.8 Conclusion
This report provides strong evidence that leadership bodies 
and membership organisations are already able to use the 
global structure provided by the Global Vision and PWDGs in 
order to describe current national strategies and mechanisms 
for workforce development, including education and training. 
A firmer, more comprehensive situational analysis must 
be undertaken, building on this initial report, one which 
sets out the way for a clear planning and action route for 
transformative development of the global workforce – 
together with a set of measurable workforce actions that will 
provide the foundations for future pharmaceutical healthcare 
delivery. Adopting this imperative is a necessity to underpin 
the future development of our profession.
References
1. International Pharmaceutical Federation (FIP). Transforming Pharmacy 
and Pharmaceutical Sciences Education in the Context of Workforce 
Development. The Hague: International Pharmaceutical Federation, 
2017. Available from: http://fip.org/publications#FIP-Education
2. International Pharmaceutical Federation (FIP). Global Vision for 
Education and Workforce. The Hague: International Pharmaceutical 
Federation, 2016. Available from: http://fip.org/educationreports
3. International Pharmaceutical Federation (FIP). Pharmaceutical 
Workforce Development Goals. The Hague: International Pharmaceutical 
Federation, 2016. Available from: http://fip.org/educationreports
4. International Pharmaceutical Federation (FIP). Nanjing statements 
on pharmacy and pharmaceutical sciences education. The Hague: 
International Pharmaceutical Federation, 2017. Available from:  
http://fip.org/educationreports
5. International Pharmaceutical Federation (FIP). Advanced Practice and 
Specialisation in Pharmacy: Global Report 2015. The Hague: International 
Pharmaceutical Federation; 2015. Available from:   
http://fip.org/educationreports
5.4 Workforce intelligence imperatives 
A fundamental understanding of the capacity of our global 
workforce is a necessary prerequisite for any transformational 
strategy or policy formation. Workforce intelligence, discussed 
in section 3.2, provides strategic workforce information 
to support workforce planning and expanding access to 
healthcare delivery. With developing and sharing workforce 
intelligence being one of the Pharmaceutical Workforce 
Development Goals (PWDG 12), it is clearly important 
to understand if the supply of pharmacists, pharmacy 
technicians and pharmacy support workers is keeping pace 
with health service and population needs. It is also, equally 
important that the education and training of pharmaceutical 
scientists is meeting the research, teaching and drug 
development needs associated with healthcare and scientific 
planning.
5.5 Academic capacity for preparing 
a transformative workforce 
The training of the next generation of pharmacists, 
pharmaceutical scientists and pharmacy support workers is 
an essential component of workforce intelligence objectives. 
Scaling up the academic capacity in pharmacy relies on the 
development of an expert academic workforce that is able 
to teach and train the next workforce generation. There are 
current gaps, drivers and opportunities in academic capacity 
development. Careful integrated planning is required to 
develop academic capacity through the academic workforce 
and section 3.3 described approaches to researching, 
developing and evaluating academic capacity.
5.6 Leadership development of the 
pharmaceutical workforce
Investing in leadership development of the health workforce 
has been shown to enhance health system organisation 
and improve patient outcomes; we have no doubt from 
the current evidence that this is particularly true for the 
pharmaceutical workforce and that strategies for leadership 
development should be visible in all countries. Countries and 
nations should ensure the creation of clear and accessible 
leadership development programmes and opportunities 
for their pharmaceutical workforce. This report provides 
good examples of where this has been the case. However, 
the implementation of leadership development should be 
integrated with other aspects of workforce development.
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Annex 1. Pharmaceutical Workforce 
Development Goals (PWDGs) 
1. Academic 
capacity
2. Foundation 
training and 
early career 
development
Academy
Focus on 
the schools, 
universities and 
education 
providers
Engagement with 
pharmaceutical 
higher education 
development 
policies and ready 
access to leaders in 
pharmaceutical science 
and clinical practice 
in order to support 
supply-side workforce 
development agendas.
Foundation training 
infrastructures in 
place for the early 
post-registration 
(post-licensing) years 
of the pharmaceutical 
workforce as a basis 
for consolidating initial 
education and training 
and progressing the 
novice workforce 
towards advanced 
practice.
• Increase the capacity to provide a competent 
pharmaceutical workforce by developing initial 
education and training programmes that are 
fit for purpose, according to national health 
resource needs (clinical practice, pharmaceutical 
science areas and stakeholders across all cadres). 
• Develop new and innovative ways to 
attract young pharmacists into all areas of 
pharmaceutical practice and science (e.g. 
encourage young pharmacists to consider 
careers in clinical academia, as preceptors/
trainers, in industrial pharmacy, regulatory 
sciences, nuclear and veterinary pharmacy, 
among others).
• Capacity building should include the ability to 
meet minimum national standards of facilities, 
educators and student support in order to ensure 
access to quality education for all students.
• Enhance interprofessional education and 
collaboration with key stakeholders, including 
governments, national and international 
pharmacy/pharmaceutical organisations and 
patient advocacy groups to achieve sustainable 
solutions for capacity development. 
• The clinical academic educator workforce needs 
more attention to training, career development 
and capacity building, which must, importantly, 
include research capacity enhancement.
• Create clear and purposeful education and 
training pathways/programmes to support 
post-registration (post-graduation) foundation 
training (clinical practice and pharmaceutical 
science areas).
• Develop early career maps and frameworks to 
support a seamless transition into early career 
practice and towards advanced practice.
• Develop structured approaches to early 
career mentoring systems to support 
novice practitioners to engage with peers 
and preceptors (in clinical practice and 
pharmaceutical science areas across the 
pharmaceutical workforce).
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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3. Quality 
assurance
4. Advanced 
and specialist 
expert 
development
Academy
Focus on 
the schools, 
universities and 
education 
providers
Professional 
development
Focus on the 
pharmaceutical
workforce
Transparent, 
contemporary and 
innovative processes for 
the quality assurance of 
needs-based education 
and training systems.
Education and training 
infrastructures in place 
for the recognised 
advancement of 
the pharmaceutical 
workforce as a basis 
for enhancing patient 
care and health system 
deliverables.
• Ensure the quality of the workforce by quality 
assuring the continuous development and the 
delivery of adequate and appropriate education 
and training; quality assurance needs to address 
academic and institutional infrastructure 
in order to deliver the required needs and 
competency-based education and training. 
• Establish standards-based global guidance 
for quality assurance of pharmacy and 
pharmaceutical science education in the context 
of local needs and practice.
• Implement fair, effective and transparent 
policies and procedures for quality assurance of 
pharmacy and pharmaceutical science education 
and training. 
• Define critical stakeholder input on development 
of adequate education and training and fair and 
effective policies, including necessary student 
input.
• Need for a common and shared understanding of 
what is meant by “specialisation” and “advanced 
practice” in the context of scope of practice and 
the responsible use of medicines.
• Ensure competency and capability of an 
advanced and expert pharmacist in all sectors 
(including specialisations extending into 
industry and administration settings) for greater 
optimisation of complex pharmaceutical patient 
care. This may now include prescribing roles 
within a recognised scope of practice.
• Systematic use of professional recognition 
programmes/systems as markers for 
advancement and specialisation across the 
workforce, including advanced pharmaceutical 
scientists.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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6. Leadership 
development
7. Service 
provision and 
workforce 
education and 
training
Professional 
development
Focus on the 
pharmaceutical
workforce
Strategies and 
programmes in place 
that develop professional 
leadership skills 
(including clinical and 
executive leadership) 
for all stages of career 
development, including 
pharmaceutical sciences 
and initial education 
and training.
A patient-centred and 
integrated health 
services foundation 
for workforce 
development, relevant 
to social determinants 
of health and needs-
based approaches 
to workforce 
development.
• Creation of programmes/strategies for the 
development of leadership skills (including tools 
and mentoring systems), to support pharmacists 
and pharmaceutical scientists through their 
careers.
• Advocacy for leadership development in 
healthcare teams, linked to collaborative 
working activities (for example, promotion of 
team-based approaches to healthcare service 
delivery). 
• Ideally, this should be linked with competency 
and foundation and early year career 
development activities.
• Systematic development of education and 
training activities based on local healthcare 
systems, their capacity and funding.
• Evidence of systematic development policies 
and strategies for the strengthening and 
transforming pharmaceutical workforce 
education and the systematic training of 
trainers/educators.
• Education providers must ensure, by the 
provision of evidence-based approaches, that 
lecturers/teachers/trainers are themselves 
appropriately trained for capability and 
competency.
• Enable the pharmaceutical workforce* and key 
stakeholders to promote health equity through 
actions related to social determinants of health.
5. Competency 
development
Clear and accessible 
developmental 
frameworks describing 
competencies and 
scope of practice for all 
stages of professional 
careers. This should 
include leadership 
development 
frameworks for the 
pharmaceutical 
workforce.
• Use of evidence-based developmental 
frameworks to support the translation of 
pharmaceutical science within scope of practice, 
across all settings and according to local/
national needs.
• Support professional career development by 
using tools, such as competency frameworks, 
describing competencies and behaviours across 
all settings.
• Evidence of clear policy that links leadership 
development (from early years) with competence 
attainment for the advancement of practice 
activities.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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9. Continuing 
professional 
development 
strategies
10. 
Pharmaceutical 
workforce 
gender and 
diversity 
balances
Professional 
development
Focus on the 
pharmaceutical
workforce
Systems
Focus on policy 
development, 
governmental 
strategy and 
planning, and 
monitoring 
systems
All professional 
development activity 
clearly linked with 
needs-based health 
policy initiatives and 
pharmaceutical career 
development pathways.
Clear strategies for 
addressing gender and 
diversity inequalities 
in pharmaceutical 
workforce 
development, 
continued education 
and training, and 
career progression 
opportunities. 
• Demonstration of strategies to address the 
gender and diversity inequalities across 
all pharmaceutical workforce and career 
development opportunities. 
• Ensure full and effective participation and 
equal opportunities for leadership at all 
levels of decision-making in pharmaceutical 
environments; avoidable barriers to participation 
for all social categories are identified and 
addressed.
• Engagement and adoption of workforce 
development policies and enforceable 
legislation for the promotion of gender and 
diversity equality; policies and cultures for the 
empowerment of all without bias.
• This should be applicable to academic capacity 
and leadership development activities.
• Evidence of an effective continuing professional 
development strategy according to national and 
local needs.
• Development of programmes to support 
professional development across all settings of 
practice and all stages of a pharmacist’s career.
• Ideally, this should be linked with all professional 
development activities across the workforce.
• Education in continuing professional 
development strategies and self-directed 
behaviours should be initiated at the student 
level.
8. Working 
with others     
in the 
healthcare 
team
Clearly identifiable 
elements of 
collaborative working 
and interprofessional 
education and training 
which should be a 
feature of all workforce 
development 
programmes and 
policies.
• Evidence of policy formation to demonstrate 
how healthcare professionals can develop and 
engage in partnerships to achieve better health 
outcomes.  
• Develop education and training strategies/
programmes to ensure collaboration within the 
pharmaceutical workforce and training   
on medicines for other healthcare professionals.
• Ideally, this should be linked with formal 
professional development activities.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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12. Workforce 
intelligence
13. Workforce 
policy formation
Systems
Focus on policy 
development, 
governmental 
strategy and 
planning, and 
monitoring 
systems
A national strategy and 
corresponding actions 
to collate and share 
workforce data and 
workforce planning 
activities (skill mixes, 
advanced and specialist 
practice, capacity). 
Without workforce 
intelligence data there 
can be no strategic 
workforce development.
Clear and manageable 
strategies to 
implement 
comprehensive needs-
based development 
of the pharmaceutical 
workforce from initial 
education and training 
through to advanced 
practice.  
• FIP should aim to have a global workforce 
compendium of case studies developed by 2019.
• Develop monitoring systems to identify 
workforce trends to enable decision making 
on deployment and supply of pharmaceutical 
workforce noting that time-lags are often 
present in these activities. 
• Ideally, this should be linked with stewardship 
and leadership for professional leadership 
bodies.
• Adopt and strengthen sound policies and 
enforceable legislation for holistic needs-based 
approaches to professional development across 
all settings and stages.
• Develop strategies where pharmaceutical 
science and professional services are the driving 
forces for this activity.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
11. Workforce 
impact 
and effect 
on health 
improvement
Evidence of the impact 
of the pharmaceutical 
workforce within 
health systems and 
health improvement. 
• Engagement with systems to measure the 
impact of the pharmaceutical workforce on 
health improvement and healthcare outcomes. 
Links with needs-based education, training and 
workforce planning.
• Gather continuous data points to monitor the 
performance of the pharmaceutical workforce.
• Ideally, this should be linked with strategies to 
enhance workforce intelligence.
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Academic capacity 
Engagement with pharmaceutical higher education 
development policies and ready access to leaders in 
pharmaceutical science and clinical practice in order to support 
supply-side workforce development agendas.
Foundation training and early career development 
Foundation training infrastructures in place for the early 
post-registration (post-licensing) years of the pharmaceutical 
workforce as a basis for consolidating initial education and 
training and progressing the novice workforce towards 
advanced practice.
Advanced and specialist expert development 
Education and training infrastructures in place for the 
recognised advancement of the pharmaceutical workforce as a 
basis for enhancing patient care and health system deliverables.
Competency development  
Clear and accessible developmental frameworks describing 
competencies and scope of practice for all stages of professional 
careers. This should include leadership development 
frameworks for the pharmaceutical workforce.
Leadership development   
Strategies and programmes in place that develop professional 
leadership skills (including clinical and executive leadership) 
for all stages of career development, including pharmaceutical 
sciences and initial education and training.
Service provision and workforce education and training   
A patient-centred and integrated health services foundation 
for workforce development, relevant to social determinants of 
health and needs-based approaches to workforce development.
Working with others in the healthcare team  
Clearly identifiable elements of collaborative working and 
interprofessional education and training which should be a 
feature of all workforce development programmes and policies.
Quality assurance 
Transparent, contemporary and innovative processes for the 
quality assurance of needs-based education and training 
systems.
PWDG general description. 
Countries/territories and Member Organisations should have:
UN Commission’s 
Recommendations 
and Immediate 
Actions
1, 3, 5, 6, 8, A
1, 3, 6
1, 3, 5, 6
1, 3, 6, 9
1, 3, 6
2
1, 3, 4, 5, 6
1, 5, 6, 8
1, 2, 3
1, 2
1
1
1
1
1, 2
1
1, 3, 5
1, 3
WHO Global 
Strategy 
Objectives, 
Milestones, and 
Policy Options
ILO OECD WHO 
Five-Year Action 
Plan Workstreams
Annex 2. PWDGs alignment with global health workforce strategies 
The Pharmaceutical Workforce Development Goals (PWDGs) are aligned with:
 
UN High-Level Commission on Health Employment and Economic Growth Recommendations and Immediate Actions; 
WHO’s Global Strategy on Human Resources for Health Objectives, Milestones and Policy Options; and ILO OECD WHO Working 
for Health: Five-Year Action Plan for Health Employment and Inclusive Economic Growth (2017–2021) Workstreams.
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PWDG general description. 
Countries/territories and Member Organisations should have:
UN Commission’s 
Recommendations 
and Immediate 
Actions
WHO Global 
Strategy 
Objectives, 
Milestones, and 
Policy Options
ILO OECD WHO 
Five-Year Action 
Plan Workstreams
Continuing professional development strategies  
All professional development activity clearly linked with 
needs-based health policy initiatives and pharmaceutical career 
development pathways.
Pharmaceutical workforce gender and diversity balances   
Clear strategies for addressing gender and diversity inequalities 
in pharmaceutical workforce development, continued education 
and training, and career progression opportunities.
Workforce impact and effect on health improvement   
Evidence of the impact of the pharmaceutical workforce within 
health systems and health improvement.
Workforce intelligence    
A national strategy and corresponding actions to collate and share 
workforce data and workforce planning activities (skill mixes, 
advanced and specialist practice, capacity). Without workforce 
intelligence data there can be no strategic workforce development.
1, 3, 6
1, 2
1, 6
1, 2, 5, 10, C, E
1
1, 2
3, 4
1, 2, 4
1, 2, 4
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Quality Assurance
The Framework is offered primarily as a 
tool — to be used in whole or in part — to 
facilitate the establishment of systems of 
quality assurance in countries where no such 
formal systems exist or for improvement of 
existing systems. Where regional similarities 
and collaborations exist, the Framework 
may also be applied at a regional rather than 
national level. Where resources or other 
constraints limit the immediate application 
of some of the principles outlined in the 
Framework, it is hoped that the document 
can serve as a “road map” for the future.
http://bit.ly/29zgrSc
Workforce Intelligence
The reports have set out to recognise the 
major challenges facing both the profession 
and global health care systems. The quality, 
scope and capability of the workforce are 
dependent on the nature of initial and life 
long professional development curricula, and 
the quality of available practitioner support 
and recognition structures. http://bit.ly/29kipF8
• Prerequisites for Quality Assurance    
   in Pharmacy Education
• Quality Criteria and Quality  
   Indicators for Pharmacy Education
• The Quality Assurance Agency
• Glossary 
2006
• Data from 17 countries and  
   territories
• Case studies from 7 countries and  
   territories [Australia, Canada,  
   Ireland, Ghana, Kenya, New  
   Zealand, United Kingdom]
2009
• Data from 56 countries and  
   territories
• Case studies from 7 countries and  
   territories [Australia, Canada, Great  
   Britain, Kenya, Jordan, Uruguay,  
   Vietnam]
• Needs-based Educational Model
• WHO chapter
2012
• Data from 90 countries and  
   territories
• Case studies from 9 countries and  
   territories [Afghanistan, Costa Rica,  
   Ghana, Great Britain, Japan, Pacific  
   Islands, Singapore, South Africa,  
   Tanzania]
• WHO chapter
2015
• Trends analysis conducted with  
   data from the workforce reports  
   (2006, 2009 and 2012)
• Data from 51 countries and  
   territories
• Higher Education  
   Institutions
• Professional   
   Associations
• Regulators
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Industry
FIPEd Tools/Description Concept/Content Aimed for:
Annex 3. Overview of FIPEd tools 
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FIP UNESCO-UNITWIN Global Pharmacy 
Education Development Network
UNITWIN/Cooperation Programme on 
Global Pharmacy Education (GPhED) was 
created within the framework of the UNESCO 
-UNITWIN Programme to fulfil objectives such 
as sharing best educational practice between 
and among education institutions and other 
education providers across borders.
Global Competency Framework (GbCF)
Promotes the development of knowledge, 
skills, attitudes and behaviours that an 
individual develops through education, 
training, development and experience as 
means to create a capable practitioner 
workforce in all healthcare professions.  
The GbCF v1 is divided in 4 clusters/areas 
of practice, 20 competencies and 100 
behavioural competencies. It is intended to 
act as a mapping tool and can be adapted 
according to the country or local needs. 
These competencies improve therapeutic 
outcomes, patients’ quality of life, scientific 
advancement and enhancement of public 
health imperatives. http://bit.ly/1TIMWe3
Pharmacy Support Workforce
Pharmacy technicians and support staff, 
pharmacists and individuals who work 
with the pharmacy support workforce in 
education, practice, regulation, development 
and promotion explore how to educate, 
develop and fully utilise the pharmacy 
support workforce within the healthcare 
system. The discussions and debate during 
this one-and-a-half-day symposium focus on 
areas of critical importance for sustainability 
of health care programmes, with a focus on 
global initiatives that support and strengthen 
the work of mid-level cadres in the delivery of 
pharmacy services.
Global Education Report 
Academic and Institutional Capacity Domain
FIPEd Global Education report provides 
a baseline on the current status, 
transformation and scaling up of pharmacy 
and pharmaceutical sciences education 
globally. http://bit.ly/29qvMko
• Network of Schools
• Centres of Excellence:
   Global – 1st one, African Centre of  
   Excellence
   [Founding partners: Ghana,  
   Uganda, Nigeria, Namibia, Zambia;  
   Malawi]
The GbCF contains:
• The drivers for the development of  
   a global competency framework.
• The process of the GbCF   
   development.
• The concept of the GbCF   
   competencies. 
• Guidance on how to use the GbCF.
• The GbCF framework.
• The domain initiated an annual  
   FIP Global Pharmacy Technician  
   and Pharmacy Support Workforce  
   Symposium in 2012, which has been  
   the basis for increased sharing and  
   practice development.
• Data from 109 countries 
   and territories
• Case studies from 14 countries  
   and territories [Chile, Great Britain,  
   Japan, Jordan, Malaysia, Namibia,  
   Philippines, Portugal, Saudi Arabia,  
   Switzerland, Thailand, UAE, USA,  
   Zimbabwe]
• Higher Education  
   Institutions
• Educators
• Professional   
   Associations
• Regulators
• Higher Education           
   Institutions
• Employers
• Industry
• CPD/CE providers
• Individual   
   Pharmacists
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Employers
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
FIPEd Tools/Description Concept/Content Aimed for:
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Continuing Professional Development/
Continuing Education (CPD/CE)
Report
CPD is “the responsibility of individual 
pharmacists for systematic maintenance, 
development and broadening of knowledge, 
skills and attitudes, to ensure continuing 
competence as a professional, throughout 
their careers”. An ongoing cyclical process 
involving: self-appraisal, developing a 
personal learning plan, taking action 
or implementing the learning plan, and 
evaluation. The report has presented the 
current trends and activities with regard 
to professional development and lifelong 
learning across countries and territories 
globally. http://bit.ly/29vvRUE
Interprofessional Education (IPE) Report
The report presents a collection of case 
studies and examples that reflect innovation 
and creativity centred on IPE. These case 
studies highlight diverse approaches 
and show that IPE is becoming a more 
mainstream education activity for students, 
trainees and practitioners worldwide. Still, 
FIPEd acknowledges the limited evidence and 
evaluation regarding the long-term impact of 
IPE initiatives. This suggests that it is needed 
to continue to follow projects such as those 
highlighted here and also encourage stronger 
interprofessional dialogue about monitoring 
and evaluation methods. http://bit.ly/29qUuUg
PharmAcademy
PharmAcademy is the go-to place for 
pharmacy educators worldwide to connect, 
and share knowledge and resources. It 
is a community site designed to connect 
pharmacy educators globally. 
http://pharmacademy.org/
Pharmacy Education Journal
Hosted by PharmAcademy, the journal is a 
peer-reviewed publication, allowing free 
submission and access to over 500 articles 
around pharmacy and pharmacy education 
workforce. 14,000 journal article donwloads 
since August 2015. http://bit.ly/2a1pdbC
• Data from 66 countries and  
   territories
• Case studies from 9 countries  
   and territories [Australia, Canada,  
   Croatia, Japan, Namibia, New  
   Zealand, Northern Ireland, Oman  
   and USA]
• A WHO case study.
• Case studies from 12 regional,  
   national and institutional-level  
   examples and initiatives   
   [Professional bodies, Accreditation  
   agencies, Student organisations,  
   Australia, China, Kenya, Lebanon,  
   Malaysia, Namibia, Philippines, UK  
   (Great Britain), Uruguay]
PharmAcademy, is an online platform 
where is possible to:
• Learn from others with 
   more experience.
• Teach and guide others with 
   less experience.
• Publish stories and news items 
   of interest to the community.
• Join or create groups of peers that  
   share common interests.
• Participate in the development 
   of pharmacy education.
• Publish on the Pharmacy Education 
   Journal.
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Employers
• Industry
• Other providers 
   of CPD/CE
• Professional   
   Associations
• Higher education   
   institutions
• Employers
• Educators
• Individual    
   Pharmacists
• Authors
FIPEd Tools/Description Concept/Content Aimed for:
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Advanced Practice and Specialisations Report 
This report is the most comprehensive 
collection of data and evidence that relates 
to practitioner advancement of practice and 
policy, and maps out a wide range of national 
initiatives worldwide. This report should be 
viewed as a first attempt to map out global 
trends and will stimulate further reportage 
and analysis as engagement in this practice 
continues to progress. http://bit.ly/29zgP3j
Transforming Our Workforce
Transforming Our Workforce is an enabling 
document that describes evidence-based 
and tested tools and mechanisms whereby 
leadership bodies and policymakers can gain 
traction for advancing the pharmaceutical 
workforce. http://bit.ly/29kipF8
• Data from 48 countries 
   and territories 
• Case studies from 17 country and  
   territories [Argentina, Australia,  
   Canada, China, India, Ireland, Japan,  
   Malaysia, New Zealand, Philippines,  
   Portugal, Singapore, South Africa,  
   Spain, Switzerland, United Kingdom 
   (Great Britain), USA]
• Development case studies of the 10  
   FIPEd tools
• Case studies from 14 national and  
   institutional-level examples and  
   initiatives [Australia, Chile, Croatia,  
   India, Jordan, Malawi, New Zealand,  
   Kenya, Serbia, Spain, Thailand, UK  
   (Great Britain)]
• Professional      
   Associations and       
   Regulatory 
   Authorities
• Employers
• Individual   
   Pharmacists
All Stakeholders
• Professional      
   Associations
• Regulators
• Higher Education     
   Institutions
• Employers
• Industry
• Individual   
   Pharmacists
FIPEd Tools/Description Concept/Content Aimed for:
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Rennie, Associate Dean (Head of School), University of Namibia, 
trennie@unam.na;
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Paraguay - Patricia Acosta, Facultad de Ciencias Químicas. 
Universidad Nacional de Asunción, guada_acosta@hotmail.
com, patri.acostar@gmail.com; Gladys Mabel Maidana, 
Facultad de Ciencias Químicas. Universidad Nacional de 
Asunción, glamaida73@gmail.com; Zully Vera, Farmacéutica, 
Facultad de Ciencias Químicas. Universidad Nacional de 
Asunción, zullyvera10@hotmail.com decano@qui.una.py;
Portugal - Luís Rhodes Baião, International Affairs 
Lead, Portuguese Pharmaceutical Society - Ordem dos 
Farmacêuticos, luis.baiao@ordemfarmaceuticos.pt; Margarida 
Caramona, (Full Professor) President of the Platform Education 
& Practice, Portuguese Pharmaceutical Society - Ordem 
dos Farmacêuticos, caramona@ci.uc.pt; Filipa A. Costa, 
(Assistant Professor) Consultant for Professional Strategic 
Planning, Portuguese Pharmaceutical Society - Ordem dos 
Farmacêuticos, filipa.costa@ordemfarmaceuticos.pt; Bruno 
Sepodes, (Assistant Professor with Habilitation) Member of 
the Council for Qualification and Admission (CQA), Portuguese 
Pharmaceutical Society - Ordem dos Farmacêuticos, 
bsepodes@ff.ulisboa.pt; 
Singapore - Lita Chew, Chief Pharmacist, Ministry of Health, 
lita_chew@moh.gov.sg; Wai Keung Chui, Associate Professor, 
Department of Pharmacy, National University of Singapore, 
phacwk@nus.edu.sg; Tuck Seng Wu, Deputy Director, 
Pharmacy Department (NUH) & President (SPC), National 
University Hospital(NUH)/ Singapore Pharmacy Council (SPC), 
tuck_Seng_Wu@nuhs.edu.sg;
South Africa - Mariet Eksteen, Professional Support and 
Development Officer, Pharmaceutical Society of South Africa, 
profoffice@pharmail.co.za; Joggie Hattingh, Vice President, 
Pharmaceutical Society of South Africa, johannes.Hattingh@
westerncape.gov.za; Sarel Malan, President, Pharmaceutical 
Society of South Africa, sfmalan@uwc.ac.za; Lorraine Osman, 
Head: Public Affairs, Pharmaceutical Society of South Africa, 
lorraine@pharmail.co.za;
Uganda - Richard Adome, Professor, Makerere University, 
rodoiadome@gmail.com; Edson Ereeta, Lecturer, Makerere 
University, wizedson@yahoo.com; Hussein Orla, Lecturer, 
Makerere University, husmoyi@gmail.com; Kalidi Rajab, 
Lecturer, Makerere University, rkalidi@gmail.com;
United Arab Emirates - Ola Ahdab, Pharmaceutical Advisor, 
Ministry of Health and Prevention, ogahmed@eim.ae; Dixon 
Thomas, Assistant Professor, Gulf Medical University, dixon.
thomas@gmail.com;
United States of America - Shaun Gleason, Associate Professor 
and Director, Distance Programs and Degrees, University of 
Colorado Skaggs School of Pharmacy and PharmSci, shaun.
gleason@ucdenver.edu; Lucinda Maine, Executive Vice 
President, American Association of Colleges of Pharmacy 
(AACP), lmaine@aacp.org; Ruth Nemire, Associate EVP, AACP, 
rnemire@aacp.org; 
Zambia - Martin Kampamba, Lecturer / Researcher, University 
of Zambia, kampambamartin@yahoo.com; Machi Hampango, 
Clinical Pharmacist / Researcher, University Teaching Hospital 
under Ministry of Health, mhampango@yahoo.com; Jimmy 
Hangoma, Clinical Pharmacist / Researcher, University 
Teaching Hospital under Ministry of Health, jimmyhangoma@
yahoo.com; Lungwani Tyson Muungo, Lecturer / Researcher, 
University of Zambia, tmuungo@yahoo.com Lungwani.
muungo@unza.zm; 
Zimbabwe - Isaac Magaya, Registrar, Pharmacist’s Council 
of Zimbabwe, imagaya@pcz.co.zw; Tsitsi Monera-Penduka, 
Lecturer, University of Zimbabwe College of Health Sciences, 
moneratg@yahoo.co.uk.
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